


## Management of the Critically Ill Patient with Cirrhosis: A Multidisciplinary Perspective

Mitra K. Nadim, Francois Durand, John A. Kellum, Josh Levitsky, Jacqueline G. O'Leary, Constantine J. Karvellas, Jasmohan S. Bajaj, Andrew Davenport, Rajiv Jalan, Paolo Angeli, Stephen H. Caldwell, Javier Fernández, Claire Francoz, Guadalupe Garcia-Tsao, Pere Ginès, Michael G. Ison, David J. Kramer, Ravindra L. Mehta, Richard Moreau, David Mulligan, Jody C. Olson, Elizabeth A. Pomfret, Marco Senzolo, Randolph H. Steadman, Ram M. Subramanian, Jean-Louis Vincent, Yuri S. Genyk



PII: S0168-8278(15)00718-7  
DOI: <http://dx.doi.org/10.1016/j.jhep.2015.10.019>  
Reference: JHEPAT 5869

To appear in: *Journal of Hepatology*

Received Date: 29 July 2015  
Revised Date: 30 September 2015  
Accepted Date: 19 October 2015

Please cite this article as: Nadim, M.K., Durand, F., Kellum, J.A., Levitsky, J., O'Leary, J.G., Karvellas, C.J., Bajaj, J.S., Davenport, A., Jalan, R., Angeli, P., Caldwell, S.H., Fernández, J., Francoz, C., Garcia-Tsao, G., Ginès, P., Ison, M.G., Kramer, D.J., Mehta, R.L., Moreau, R., Mulligan, D., Olson, J.C., Pomfret, E.A., Senzolo, M., Steadman, R.H., Subramanian, R.M., Vincent, J-L., Genyk, Y.S., Management of the Critically Ill Patient with Cirrhosis: A Multidisciplinary Perspective, *Journal of Hepatology* (2015), doi: <http://dx.doi.org/10.1016/j.jhep.2015.10.019>

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

## Management of the Critically Ill Patient with Cirrhosis: A Multidisciplinary Perspective

Mitra K. Nadim<sup>1</sup>, Francois Durand<sup>2</sup>, John A. Kellum<sup>3</sup>, Josh Levitsky<sup>4</sup>, Jacqueline G. O'Leary<sup>5</sup>,  
Constantine J. Karvellas<sup>6</sup>, Jasmohan S. Bajaj<sup>7</sup>, Andrew Davenport<sup>8</sup>, Rajiv Jalan<sup>9</sup>, Paolo Angeli<sup>10</sup>,  
Stephen H. Caldwell<sup>11</sup>, Javier Fernández<sup>12</sup>, Claire Francoz<sup>2</sup>, Guadalupe Garcia-Tsao<sup>13</sup>, Pere Ginès<sup>12</sup>,  
Michael G. Ison<sup>14</sup>, David J. Kramer<sup>15</sup>, Ravindra L. Mehta<sup>16</sup>, Richard Moreau<sup>2</sup>, David Mulligan<sup>17</sup>,  
Jody C. Olson<sup>18</sup>, Elizabeth A. Pomfret<sup>19</sup>, Marco Senzolo<sup>20</sup>, Randolph H. Steadman<sup>21</sup>,  
Ram M. Subramanian<sup>22</sup>, Jean-Louis Vincent<sup>23</sup>, and Yuri S. Genyk<sup>24</sup>

<sup>1</sup>Division of Nephrology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA

<sup>2</sup>Hepatology and Liver Intensive Care, Hospital Beaujon, Clichy, University Paris VII Diderot, Paris, INSERM U1149, Paris and Département Hospitalo-Universitaire UNITY, Clichy, France

<sup>3</sup>Department of Critical Care Medicine, University of Pittsburgh, Pittsburgh, PA, USA

<sup>4</sup>Division of Gastroenterology and Hepatology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA

<sup>5</sup>Division of Hepatology, Baylor University Medical Center, Dallas, Texas, USA

<sup>6</sup>Division of Critical Care Medicine and Gastroenterology/Hepatology, University of Alberta, Edmonton, AB, Canada

<sup>7</sup>Division of Gastroenterology, Hepatology, and Nutrition, Virginia Commonwealth University, McGuire VA Medical Center, Richmond, VA, USA

<sup>8</sup>University College London Center for Nephrology, Royal Free Hospital, University College London Medical School, London, UK

<sup>9</sup>Liver Failure Group, UCL Institute for Liver and Digestive Health, UCL Medical School, Royal Free Hospital, London, UK

<sup>10</sup>Unit of Hepatic Emergencies and Liver Transplantation, Department of Medicine, DIMED, University of Padova, Padova, Italy

<sup>11</sup>Division of Gastroenterology and Hepatology University of Virginia Medical Center, Charlottesville, Virginia, USA

<sup>12</sup>Liver Unit, Hospital Clinic de Barcelona, University of Barcelona, Institut d'Investigacions Biomèdiques August Pi Sunyer, Centro d'investigación biomédica en red de enfermedades hepáticas y digestivas, Barcelona, Spain

<sup>13</sup>Division of Digestive Diseases, Yale University School of Medicine, New Haven, CT, USA

<sup>14</sup>Divisions of Infectious Diseases and Organ Transplantation, Northwestern University Feinberg School of Medicine, Chicago, IL, USA

<sup>15</sup>Aurora Critical Care Service, Aurora Health Care, Milwaukee, WI, USA

<sup>16</sup>Division of Nephrology, University of California San Diego, San Diego, CA, USA

<sup>17</sup>Section of Transplantation and Immunology, Department of Surgery, Yale-New Haven Hospital Transplantation Center, Yale School of Medicine, New Haven, CT, USA

<sup>18</sup>Division of Hepatology, University of Kansas Hospital, Kansas City, KS, USA

<sup>19</sup>Department of Transplantation and Hepatobiliary Diseases, Lahey Hospital and Medical Center, Burlington, MA, USA

<sup>20</sup>Multivisceral Transplant Unit, Department of Surgical and Gastroenterological Sciences, University Hospital of Padua, Padua, Italy

<sup>21</sup>Department of Anesthesiology, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, CA, USA

<sup>22</sup>Divisions of Gastroenterology and Pulmonary & Critical Care Medicine, Emory University Hospital, Atlanta, GA, USA

<sup>23</sup>Department of Intensive Care, Erasme Hospital, Université Libre de Bruxelles, Brussels, Belgium

<sup>24</sup>Division of Hepatobiliary Surgery and Abdominal Organ Transplantation, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA

### Corresponding Author:

Mitra K. Nadim, MD

Associate Professor of Clinical Medicine

Division of Nephrology

Keck School of Medicine

University of Southern California

1520 San Pablo St., Suite 4300

Los Angeles, CA 90033

[nadim@usc.edu](mailto:nadim@usc.edu)

**Word Count:** 7585

**Number of Figures and Tables:** 3 tables, 6 figures, 4 supplemental tables, 3 supplemental figures

**List of Abbreviations in the Order of Appearance:**

ICU: intensive care unit; ACLF: acute on chronic liver failure; CLIF: chronic liver failure organ failure; AST: American society of transplantation; ASTS: American society of transplant surgeons; EASL: European association for the study of the liver; AKI: acute kidney injury; Scr: serum creatinine; KDIGO: Kidney disease improving global outcomes; UO: urine output; eGFR: estimated glomerular filtration rate; GFR: glomerular filtration rate; MDRD-6: Modified Diet in Renal Disease 6; ADQI: acute dialysis quality initiative; ICA: international club of ascites; AKIN: acute kidney injury network; HRS: hepatorenal syndrome; CKD: chronic kidney disease; RRT: renal replacement therapy; ATN: acute tubular necrosis; NGAL: neutrophil gelatinase-associated lipocalin; KIM-1: kidney injury molecule; CRRT: continuous renal replacement therapy; PAC: pulmonary artery catheter; ScvO<sub>2</sub>: venous oxygen saturation; SVV: stroke volume variation; PPV: pulse pressure variation; StO<sub>2</sub>: tissue oxygen saturation; HES: hydroxyethyl starch; SBP: spontaneous bacterial peritonitis; AI: adrenal insufficiency; GIB: gastrointestinal bleed; TMP-SMX: trimethoprim/sulfamethoxazole; CRP: c-reactive protein; MALDI-TOF: matrix-assisted laser desorption/ionization time of flight; BAL: bronchial lavage; FFP: fresh frozen plasma; INR: internationalized ratio; PT: prothrombin time; PCC: prothrombin complex concentrates; HE: hepatic encephalopathy; EEG: electroencephalogram; WHC: west-haven criteria; CHES: clinical HE staging scale (CHES); HESA: HE scoring algorithm; MO-log: modified orientation log; GCS: glscom coma scale; PEG: polyethylene glycol (PEG); LOLA: L-ornithine L-aspartate

**Key Words:** cirrhosis, acute on chronic liver failure, hepatorenal syndrome, renal dysfunction, intensive care, cardio-pulmonary dysfunction, infectious disease, hepatic encephalopathy, hematologic dysfunction

**Conflict of Interest**

MKN is a consultant for Ikaria and Baxter and an Advisor and on the Data and Safety Monitoring board for La Jolla Pharmaceutical Company. FD is a consultant for Astellas, Novartis, Gilead and Bristol-Myers Squibb and has received research funding from Gilead and Astellas Pharma. JAK is a consultant for Fresenius, Baxter, Grifols, Astute Medical, Alere, AM Pharma, Spectral, Cytosorbents, Alung, Atox Bio and Bard, has received grant support from Gambro, Baxter, Bard, Astute Medical, Alere, Spectral, Grifols, Cytosorbents, Kaneka, Atox Bio and has licensing agreement with Astute Medical, Spectral and Cytosorbents. JGO is a consultant for Grifols, Gilead, Abbvie, Novartis, Astellas, Fisher Scientific and has received grant support from Grifols. PG is a consultant and on the advisory board for Ferring Pharmaceuticals and Ikaria and has research funding from Grifols and Sequana Medical. JSB is a consultant for Salix, Norgine and Grifols. RJ has received research funding from Vital Therapies, has served on Scientific Advisory Board for Conatus Pharma, received lecture fees from Gambro, has on-going research collaboration with Gambro, Grifols, is the Principal Investigator of an Industry sponsored study

(Sequana Medical), inventor for a drug, L-ornithine phenyl acetate which UCL has licensed to Ocera Therapeutics and the founder of UCL spin-out company Yaqrit Ltd. and Cyberliver Ltd. SHC is a consultant and has received research funding from Vital Therapies. MGI has research support from Anolinx, Chimerix, Gilead, Glaxo Smith Klein, Viro Pharma, is a consultant for Biota, Chimerix, Farmark, Genentech/Roche, Shionogi, Adamas, BioCryst, Cellex, Clarassance, Glaxo Smith Klein, GenMarkDx, Romark, Toyama/MediVector, NexBio, Theraclone, Vertex and on the Data and Safety Monitoring Board for Abbott, Jansen/Vertex. JCO is a consultant for Baxter. YSG is a consultant for Baxter. The rest of the authors have disclosed no conflict of interest with any company.

### **Financial Support**

This conference was supported by unrestricted educational grants from Ikaria, Salix Pharmaceuticals, Gilead, Grifols, Baxter Healthcare Corporation and Astellas Pharma France. None of the companies that provided financial support for this meeting were involved in any way in the organization of the meeting, the decision regarding invited faculty, the design and contents of the meeting, the collection, management, analysis, and interpretation of the data, and preparation, review, or approval of the manuscript. None of the authors received any honorarium for their participation in this meeting.

### **Author's Contribution**

All authors contributed to the literature review, figure and table development and manuscript preparation as it pertained to their working group. The organizing committee edited the final version of the manuscript. All authors reviewed and approved the final manuscript.

Organizing Committee: Mitra K. Nadim, Francois Durand, John A. Kellum, Josh Levitsky and Yuri S. Genyk

### Working Groups

1. Renal Dysfunction: Andrew Davenport (group leader), Guadalupe Garcia-Tsao, Pere Ginès, John A. Kellum, Ravindra L. Mehta and Mitra K. Nadim
2. Cardiopulmonary Dysfunction: Francois Durand (group leader), Yuri S. Genyk, Josh Levitsky, Mitra K. Nadim, Jody C. Olson, Ram M. Subramanian and Jean-Louis Vincent
3. Prevention and Management of Infections: Jacqueline G. O'Leary (group leader), Javier Fernández, Michael G. Ison, Richard Moreau and David Mulligan
4. Alterations in Hemostasis: Constantine J. Karvellas (group leader), Stephen H. Caldwell, Elizabeth A. Pomfret, Marco Senzolo and Randolph H. Steadman
5. Neurologic Dysfunction: Jasmohan S. Bajaj (group leader), Paolo Angeli, Claire Francoz, Rajiv Jalan and David J. Kramer

## Introduction

The occurrence of complications in patients with cirrhosis such as jaundice, ascites, encephalopathy, infection, renal dysfunction or variceal bleeding requiring hospitalization alters the natural history of the disease with an increase in 5-year mortality as high as 40-50% (1). A significant proportion of these patients with acute decompensation require management in the intensive care unit (ICU) with organ support and have a high rate of in-hospital mortality. This category of patients with cirrhosis, acute decompensation and organ failure has been recently classified by a consensus conference as having acute on chronic liver failure (ACLF) (2). Diagnosis of ACLF is made using the Chronic Liver Failure Organ Failure (CLIF) score (**Table 1**) and its prognosis is determined using the CLIF-ACLF score ([www.clifconsortium.com](http://www.clifconsortium.com), ACLF calculator). ACLF occurs in approximately 30% of hospitalized cirrhotic patients who present with a complication following an identified or unidentified precipitating event, is characterized by hepatic and / or extra-hepatic organ failures, and is associated with a 28-day mortality rate 15 times higher than patients without ACLF (2, 3). In the US, each year, approximately 200,000 patients with cirrhosis are hospitalized of which approximately 10% require ICU care (3). The cost of providing health care to these patients amounts to about \$13 billion per year (4).

ACLF is a newly recognized and complex condition in which the host response to injury and the type and number of organ failures all play important roles in determining the prognosis of the patient (2, 3). At present, the most effective management of patients with ACLF is unclear because of paucity of clinical trial data and lack of evidence-based guidance. The occurrence of ACLF increases the mortality risk, but the prognosis might be improved by optimal ICU management involving multiple disciplines, including hepatology, critical care, nephrology, infectious disease and transplant surgery. It is with this in mind that a Consensus meeting, endorsed by the American Society of Transplantation (AST), American Society of Transplant Surgeons (ASTS) and European Association For the Study of the Liver (EASL), was organized whereby a group of invited experts in the field of liver transplantation reviewed the current knowledge of diagnostic approaches and treatment strategies that currently exist in the critical care management of patients with ACLF who are awaiting liver transplantation. The goal was to develop a consensus of opinions, based on best available evidence, on optimal practices and to articulate a research agenda to focus on important unanswered questions.

## Methods

Prior to the conference, the organizing committee identified topics relevant to the management of patients with ACLF. A diverse international panel representing multiple relevant disciplines (nephrology, hepatology, transplant surgery, critical care / anesthesiology and infectious disease), from a variety of countries and scientific societies based on their expertise in this topic were assembled. Panelists were assigned to five person work groups, with each work group addressing one key topic. Prior to the conference, each group identified a list of key questions, conducted a systematic literature search and generated a bibliography of key studies. We then conducted a 2½ day conference, whereby work groups assembled in breakout sessions, as well as in plenary sessions where their findings were presented, debated and refined. A series of summary statements was then developed during the breakout sessions and presented to the entire group, revising each statement as needed until a final version was agreed upon all members of the consensus meeting.

Each work group conducted literature searches related to their topic questions via MEDLINE, PubMed, and the bibliographies of all articles that met the search criteria. The majority of the work group resources were devoted to review of randomized trials, as these were deemed to be most likely to provide data to support level 1 recommendations with high quality evidence. The quality of the overall evidence and the strength of recommendations were graded using the Grading of Recommendations Assessment, Development and Evaluation system (**Suppl. Table 1**) (5). Recommendations were “Not Graded” if they were not based on systematic evidence and used to provide guidance where the topic did not allow adequate application of evidence.

## RENAL DYSFUNCTION

Acute kidney injury (AKI) occurs in up to 50% of patients admitted with cirrhosis and represents one of the criteria that define ACLF (6-9). This increased risk of AKI is due to the combination of an impaired effective arterial blood volume secondary to arterial vasodilation, with increased intra-renal vasoconstriction and impaired renal autoregulation. Factors such as bacterial infections and gastrointestinal bleeding that further impair circulatory status and reduce renal perfusion can precipitate AKI (10-12). The development of AKI



not only increases the risk of mortality, but also reduces kidney function in the long-term following liver transplantation (13-17).

## Defining and Classifying Renal Dysfunction

### Recommendations

1. *We recommend that serum creatinine (Scr) values be interpreted with caution in cirrhotic patients especially those with ascites and fluid due to overestimation of values (1A).*
2. *Diagnose and stage AKI in patients with liver disease guided by Kidney Disease Improving Global Outcomes (KDIGO) Scr and urine output (UO) criteria (Ungraded).*
3. *Use a value of Scr obtained in the previous 3 months as baseline Scr. In patients with more than one value within the previous 3 months, the value closest to the hospital admission when the patient was stable can be used as the baseline. In patients without a baseline Scr value, the admission Scr should be used as the reference Scr (Ungraded).*
4. *We do not recommend the use of estimated glomerular filtration rate (eGFR) equations for assessing renal function in patients with AKI (1D).*

**Rationale.** In the setting of cirrhosis, Scr tends to overestimate renal function due to decreased creatine production by the liver, protein calorie malnutrition, muscle wasting, reduced physical activity and enlarged volume of distribution in the setting of fluid overload (18). In addition, in the setting of AKI, Scr can lag by several hours to days despite a decrease in glomerular filtration rate (GFR) especially in the setting of fluid overload (19, 20). Serum cystatin C has not been shown to be superior to Scr in patients with cirrhosis (18, 21, 22). Exogenous clearance markers such as inulin and iothalamate, are confounded by changes in volume of distribution, due to ascites and extracellular volume expansion. Among creatinine-based equations, it has been shown that the Modified Diet in Renal Disease 6 (MDRD-6) is the most accurate in cirrhosis (23-25). Equations based on cystatin C, with or without Scr (i.e., CKD-EPI creatinine-cystatin C equation) may be superior to creatinine-based equation (26, 27) however all equations tend to overestimate the true GFR and have been developed in study populations consisting of patients with chronic kidney disease (CKD) with stable Scr (28, 29).

In 2010, the Acute Dialysis Quality Initiative (ADQI) and the International Club of Ascites (ICA) proposed adaptation of the Acute Kidney Injury Network (AKIN) criteria to define AKI in patients with cirrhosis which has been validated in several studies of hospitalized patients with cirrhosis (6-8, 30-35). These criteria were irrespective of whether the presumed cause of AKI was related to a functional or structural disorder. As such, type 1 hepatorenal syndrome (HRS) was categorized as a specific type of AKI (6-8, 32-35). The current definitions of AKI depend on absolute or relative changes in Scr and urine output (**Table 2**) (30, 36-38). UO has been found to be a sensitive and early marker for AKI in ICU patients and to be associated with adverse outcomes (39-41). Although the severity of oliguria in the diagnosis of AKI has yet to be validated in patients with cirrhosis, worsening oliguria or development of anuria should be considered as AKI until proven otherwise, regardless of any rise in Scr (**Fig. 1**).

There remains some debate as to the most appropriate reference Scr to use to diagnose and stage AKI (38, 42-44). The ICA recently suggested that a baseline Scr result within the previous 3 months should be used as the reference, if available, or if no baseline exists, then the admission Scr can be used as the reference (38). Note that sometimes the reference Scr will only become apparent after renal function recovers. These patients have a better prognosis compared to those who do not recover renal function but still are at increased risk for CKD or death or over the ensuing months to years (38).

## Evaluation and Management of AKI

### *Recommendations*

1. *We recommend replacement of isotonic crystalloids in cases of volume loss due to diarrhea or over diuresis (1D), blood in cases of acute gastrointestinal hemorrhage (1D), and 20-25% albumin for infections (1A), suspected type-1 HRS (1A) or in cases where the cause of AKI is unclear (1D).*
2. *We recommend to start treatment with vasoconstrictors and 25% albumin (1 gm/kg day 1 followed by 20-40 gm /day) either when patients meet the ICA criteria of type-1 HRS (1A), or when there are evident signs of AKI progression as judged by a rapid increase in Scr when other causes of AKI have been ruled out (Fig. 2) (Ungraded).*



3. *In patients with type-1 HRS responding to vasoconstrictors and albumin with a decrease in Scr during the first days we recommend discontinuing treatment when Scr levels has reached or is close to baseline. If baseline Scr is unknown, we recommend discontinuing treatment when Scr does not decrease further after 3 days of treatment. In non- responders, we recommend vasoconstrictors and albumin be stopped after a maximum of 7 days (1D).*
4. *We recommend that in patients with evidence of worsening AKI, worsening fluid overload with > 10% total body weight despite diuretic therapy or worsening acid-base status then renal replacement therapy (RRT) should be initiated (1D).*

**Rationale.** AKI should be suspected in the presence of increase Scr or decrease UO (**Fig. 1**). The diagnosis of type-1 HRS is particularly important since early initiation of treatment increases the likelihood of HRS resolution and may improve survival (45). An important step in the differential diagnosis of kidney dysfunction is to exclude parenchymal kidney disease as cause of AKI or AKI on a background of CKD (**Suppl. Fig. 1**).

Plasma volume expansion is an important step not only in the treatment but also in the differential diagnosis of the cause of AKI and the type of fluid needed for resuscitation should be tailored based on the etiology of AKI (**Suppl. Fig. 1**). It is important to emphasize that patients with cirrhosis and AKI have reduced renal sodium and water excretion. Therefore, caution should be used with the administration of crystalloids to avoid development of significant fluid retention and edema. If kidney function does not improve despite a trial of plasma expansion, type-1 HRS is the most likely diagnosis but still needs to be distinguished from acute tubular necrosis (ATN). Several recent studies have shown that urine biomarkers, such as neutrophil gelatinase-associated lipocalin (NGAL), interleukin-18 (IL-18), kidney injury molecule-1 (KIM-1) in addition to urine microalbuminuria or fractional excretion of sodium may be helpful in not only diagnosing AKI earlier but also shedding light on the etiology of AKI (HRS vs ATN) and potentially help identify patients who are less likely to benefit from volume resuscitation and vasopressor therapy (32, 46-51).

#### Type-1 HRS Treatment

Patients in whom other causes of AKI have been ruled out should receive treatment for type-1 HRS with vasoconstrictors (**Suppl. Table 2**), which in conjunction with albumin, constitute the main therapy for type-1 HRS (**Figure 2**) (45). Until now, vasoconstrictors have been typically initiated only when Scr reaches a threshold level of  $>2.5$  mg/dL, however, type-1 HRS reversal and survival rates may improve with earlier institution of vasoconstrictor therapy (52). Countries where terlipressin is not available, the combination of octreotide/midodrine can be initiated, and if there is no decline in Scr within a maximum of 3 days then the patient should be transferred to the ICU for a trial of norepinephrine(53, 54). All patients receiving vasoconstrictors should be monitored for ischemic and cardiovascular complications. Vasoconstrictors are not recommended in patients with pre-existing ischemic heart disease, cerebrovascular disease, peripheral arterial disease, hypertension or asthma.

#### Renal Replacement Therapy (RRT)

The initiation of RRT should be made on clinical grounds, including, volume overload, metabolic acidosis, hyperkalemia and hyponatremia not responding to medical management, and diuretic intolerance / resistance. RRT should be considered even in nonoliguric patients if the daily fluid balance cannot be maintained as even or negative (**Suppl. Fig. 2**). Continuous renal replacement therapy (CRRT) allows the option of adjusting dialysate and replacement solution flow rates or composition to allow for the slower correction of serum sodium in patients with hyponatremia and provides greater cardiovascular stability compared to standard intermittent hemodialysis (55, 56).

#### **CARDIO-PULMONARY DYSFUNCTION**

Circulatory changes in cirrhotic patients are characterized by increased cardiac output, peripheral vasodilatation, decreased systemic vascular resistance (SVR) and decreased oxygen extraction. Circulatory failure in cirrhotic patients with ACLF is distributive in nature and characterized by a greater decrease in arterial pressure associated with signs of impaired tissue perfusion. Marked splanchnic vasodilatation results in a state of effective hypovolemia with water and sodium retention (11). The activation of the renin-angiotensin system and other vasoconstriction systems results in renal vasoconstriction. This leads to impaired renal function, which can be further exacerbated by abdominal

compartment syndrome in patients with tense ascites. Circulatory shock leads to further deterioration in liver function in patients with cirrhosis and contributes significantly to prognosis (57, 58).

## Goals of Resuscitation

### Recommendations

1. *Achieve a mean arterial pressure that ensures organ perfusion (ungraded). We recommend individualizing the mean arterial pressure goal; in a cirrhotic patient in shock, a mean arterial pressure  $\geq 60$  mmHg is usually appropriate (1D).*
2. *We do not suggest use of a specific goal for blood lactate or venous oxygen saturation (ScvO<sub>2</sub>) during fluid resuscitation (2C).*
3. *We recommend therapeutic paracentesis in patients with tense ascites (1A).*
4. *We recommend careful attention and monitoring of patients, preferably with a pulmonary artery catheter (PAC) or echocardiography, during fluid resuscitation to avoid development of fluid overload (1D).*

**Rationale.** In septic shock, the first goal is to achieve a mean arterial pressure of 60 mmHg or more (59). No specific target for ventricular filling pressure, or volume, lactate, ScvO<sub>2</sub>, can be recommended (60). Trends are more informative than absolute values. A growing body of evidence suggests that over-zealous fluid administration with increases in tissue edema and total body water may lead to organ dysfunction and poor outcomes and thus, careful attention to fluid resuscitation is mandatory (61-65). Cirrhotic patients are particularly susceptible to development of extracellular edema, ascites and pulmonary edema with aggressive fluid administration. Increased edema formation and ascites can worsen intra-abdominal hypertension with resultant intra-abdominal compartment syndrome with decreases in respiratory compliance and impaired renal and cardiac function (66). Systematic measurement of intra-abdominal pressure is not recommended in patients with ascites however, in critically ill cirrhotic patients with tense ascites and clinical suspicion of abdominal hypertension, therapeutic paracentesis is recommended with albumin replacement as described below.

## Monitoring of Circulatory Status

### **Recommendations**

1. ***We recommend placement of arterial catheters to guide therapy patients with circulatory shock receiving ongoing resuscitation (1D).***
2. ***We recommend ensuring adequate venous access for fluids in patients with circulatory shock receiving ongoing resuscitation (1D); this will often require central venous access.***
3. ***We recommend the use of echocardiography as a first line option for initial evaluation of circulatory failure (1C).***
4. ***We recommend repeated measurements of blood lactate levels even though the interpretation may be complicated by the impaired clearance in cirrhosis (1A).***
5. ***We suggest the use of pulmonary artery catheter (PAC) for monitoring in patients with respiratory failure and/or persistent hemodynamic instability (2D).***

**Rationale.** In patients with circulatory shock, central venous and arterial lines should be routinely inserted (**Fig. 3**). Detailed hemodynamic monitoring may be needed, thus the first objective is to characterize the type of shock even though distributive shock is by far the most common pattern. Thereafter, secondary objectives are to assess myocardial function, to ensure venous return is adequate, vascular tone is restored, tissue oxygenation is optimized and to evaluate response to therapy (60).

The complex circulatory alterations in cirrhosis, especially patients with ACLF, complicate assessment of hemodynamics. Minimally invasive methods of assessing hemodynamic parameters such as stroke volume variation (SVV) and pulse pressure variation (PPV) have gained popularity in the ICU, however in patients who are spontaneously breathing, these methods have limited utility (**Table 3**) (67, 68). Such monitors have failed to demonstrate acceptable accuracy in cirrhotic patients undergoing liver transplantation, which further questions their role in the ICU (69).

Dynamic assessments of circulatory function including echocardiography are superior to static measures (70). Changes in central venous pressure (CVP) in response to volume challenge is more instructive than a single measurement and, when properly applied, passive leg raise may be used to assess volume responsiveness (68). Increased intra-abdominal pressure may result in increased CVP without improving cardiac preload. In patients with suspected right ventricular dysfunction or in patients with pulmonary hypertension, a PAC may be indicated to guide resuscitation. PAC may also be useful in

the management of complex cases in which fluid management is critical such as patients with respiratory failure or when clinical or radiologic findings do not allow differentiation of high pressure vs. low pressure pulmonary edema and pulmonary infection.

Indirect markers of circulatory/tissue oxygenation status should be interpreted with caution in the context of cirrhosis; the levels in circulatory failure are higher in patients with cirrhosis as compared to patients without cirrhosis due to impaired liver function resulting in decreased lactate clearance (71). Thus, trends in serum lactate may be more informative than absolute values. A substantial part of fluid administered goes to the splanchnic circulation without restoring central effective volume. Worsening of tissue oxygen saturation ( $StO_2$ ), measured by near infrared spectroscopy, was recently shown to be associated with a poor prognosis in patients with cirrhosis (72). Whether  $StO_2$  as well as  $ScvO_2$  could be useful for monitoring is unknown.

## Choice of Fluid Therapy

### *Recommendations*

1. *We recommend use of crystalloid solutions as the initial fluid of choice in volume depleted patients (10-20 mL/kg) (1C).*
2. *We recommend use of albumin (8g/L of ascites removed) following large volume paracentesis (>5L) (1B).*
3. *We recommend patients with SBP should receive concentrated albumin (1.5 g/kg on day one followed by 1 g/kg on day 3) (1B).*
4. *We suggest that in patients with suspected bacterial infection fluid resuscitation with crystalloids and a proportion of 4-5% albumin may be an option (2D).*
5. *We recommend against the use of hydroxyethyl starch (HES) (1B).*

**Rationale.** In volume depleted patients with distributive shock, crystalloids (normal 0.9% saline) are recommended at an initial dose of 10-20 mL/kg (73). However, balanced salt solutions (such as PlasmaLyte®) may be preferred to normal saline in patients with hyperchloremic acidosis (74) and in patients with relative hyperchloremia (e.g. those with “normal” chloride in the setting of low serum sodium).

In patients with evidence of fluid overload (tense ascites, generalized edema, CVP > 12 mmHg) fluid administration should be discontinued.

There are theoretical benefits to the use of albumin in patients with cirrhosis beyond simple volume expansion based on its numerous biological properties (75). Patients with cirrhosis should receive albumin in 3 specific situations: spontaneous bacterial peritonitis (SBP), large volume paracentesis and type-1 HRS (76). Randomized controlled trial has shown that in patients with SBP, antibiotics plus albumin are superior to antibiotics alone in prevention of the occurrence of type-1 HRS (45, 77). Albumin is also recommended in patients with large volume paracentesis as it is superior to crystalloids in preventing post-paracentesis circulatory dysfunction (78-80). In cirrhotic patients with infections other than SBP, two controlled trials showed that the administration of albumin in combination with antibiotics did not improve survival, however the incidence of AKI was significantly lower with albumin (81, 82).

HES solutions may have harmful effects in patients with sepsis and should be avoided due to potential nephrotoxicity (83, 84).

## **Pharmacological Management of Persistent Shock**

### **Recommendations**

- 1. We recommend the use of norepinephrine as the first line vasopressor agent (1A). Vasopressin or terlipressin are appropriate second line agents for persistent hypotension (1B).**
- 2. A trial of hydrocortisone 200-300 mg/day in divided doses in patients with refractory hypotension should be started and stopped following improvement in hemodynamics (1C).**

**Rationale.** Norepinephrine is the first line agent as this agent is associated with fewer adverse events (85). Vasopressin or terlipressin may be used as second line agents and have demonstrated improvements in hemodynamics and norepinephrine sparing in patients with cirrhosis (53, 86-89).

Adrenal insufficiency (AI) is common in critically ill patients with cirrhosis, however, it could also be a feature of liver disease *per se* and not simply related to critical illness (90-93). So far, there has not been a consensus about the appropriate method for the precise AI diagnosis in patients with cirrhosis. The use of corticosteroids in critically ill patients with cirrhosis has been associated with a significant reduction in vasopressor doses and higher rate of shock reversal (94-96). Survival benefit however, was demonstrated



in some (91, 95) but not all studies (94, 96). In patients with increasing vasopressor requirements hydrocortisone 200-300 mg/day in divided doses should be administered (93, 97).

## PREVENTION AND MANAGEMENT OF INFECTIONS

Patients with advanced cirrhosis are at increased risk for bacterial and fungal infections because of several key factors: 1) dysbiosis (i.e., alterations of the gut microbiome 2) small intestinal bacterial overgrowth, 3) increased bacterial translocation 4) immunocompromised state, and 5) increased rate of resistant organism colonization (2, 10, 98-103). Once infection occurs and leads to ACLF (10, 23), the compensatory anti-inflammatory response increases the risk for subsequent infections with further worsening in prognosis (3, 104). Following an episode of infection, the decision to reactivate a patient for transplant should balance the benefit of transplant with the risk of post-operative infectious complications (**Table 4**).

### Antibiotic Prophylaxis

#### Following Gastrointestinal Bleeding (GIB)

##### **Recommendations**

1. ***We recommend immediate antibiotic prophylaxis for 7 days following GIB (1A), although the absolute benefit and required duration are not clear in patients with compensated cirrhosis after rapid control of bleeding (2D).***
2. ***We recommend IV ceftriaxone for GIB prophylaxis in patients with severely decompensated cirrhosis with active bleeding who are on a quinolone at admission or have a history of quinolone resistant infection. Quinolones are recommended in the remaining patients (1A).***

**Rationale.** Following an episode of GIB, antibiotic prophylaxis is currently recommended (105) as it decreases the risk of infection, rebleeding, infection related and all-cause mortality (106, 107). Most studies evaluated 7 days of antibiotic therapy, but in patients with rapid control of bleeding and less severe liver disease, shorter course therapy may be acceptable. Controversy remains regarding the necessity of antibiotic prophylaxis in compensated cirrhosis. When administering antibiotic prophylaxis after GIB, the majority of studies utilized norfloxacin 400 mg orally twice daily or ceftriaxone 1 gm intravenously daily

(106, 108). Oral ciprofloxacin has limited data on its efficacy, but would be the preferred alternative where norfloxacin is unavailable. In patients with more advanced liver disease with at least 2 of the following: ascites, hepatic encephalopathy, jaundice, or severe malnutrition, superior results were achieved with IV ceftriaxone (95, 109). IV ceftriaxone should also be considered in patients with active GIB, on a quinolone at admission, with a history of a quinolone resistant infection, or who live in regions with a high prevalence ( $\geq 20\%$ ) of quinolone resistance.

### Spontaneous Bacterial Peritonitis (SBP)

#### **Recommendations**

1. ***We recommend primary SBP prophylaxis only in patients with low protein ascites (<1.5 g/dL) and renal and/or liver impairment and secondary SBP prophylaxis in all patients (1A).***
2. ***We recommend SBP prophylaxis with norfloxacin 400 mg daily. Ciprofloxacin 500 mg or trimethoprim/sulfamethoxazole (TMP-SMX) 160/800mg daily can be used if norfloxacin is unavailable (1A).***
3. ***We do not recommend weekly quinolones (1C) nor probiotics alone (2C) or in combination with antibiotics (2D) for SBP prophylaxis.***
4. ***Resistant infections can occur in patients on SBP prophylaxis, after which the ideal antibiotic prophylactic strategy is not known (2D).***

**Rationale.** Current guidelines only recommend primary SBP prophylaxis in highly selected patients: ascitic fluid total protein <1.5 g/dL and renal impairment (Scr  $\geq 1.2$  mg/dL, BUN  $\geq 25$  mg/dL or serum Na  $\leq 130$  mEq/L) or Child Pugh Turcotte  $\geq 9$  with serum bilirubin  $\geq 3$  mg/dL. A meta-analysis confirmed improved outcomes in patients receiving primary prophylaxis with a decrease in serious infections, SBP and mortality (110), however, development of resistant infections is the major concern with this approach.

When choosing an antibiotic for prophylaxis, norfloxacin 400 mg/day is the best studied (111-113). In areas where norfloxacin is unavailable ciprofloxacin 500 mg or TMP-SMX 160/800 daily can be used (114). Weekly quinolone therapy is not recommended because of inferior efficacy and increased risk of resistance. Limited data has not demonstrated reduced risk of SBP with probiotic administration alone or in

combination with antibiotics (115). Since no clinical studies have been performed, SBP prophylaxis in patients with prior antibiotic-resistant bacteria is a critical area of research required.

#### Other Antibiotic Prophylactic Strategies

##### **Recommendations**

1. ***We suggest universal decontamination with intranasal mupirocin and chlorhexidine baths of ICU patients as part of a hospital wide plan to decrease bloodstream infections (2B).***
2. ***We recommend antibiotic-impregnated catheters only when a comprehensive strategy to reduce the rate of central line associated blood stream infections has failed and the line will remain >5 days (1A).***

**Rationale.** Universal decontamination of patients, using twice daily intranasal mupirocin and daily chlorhexidine baths, is associated with a statistically significant decrease in bloodstream infections (116). While studies of this intervention included few cirrhotic patients, the results likely apply to this population.

The best approach to prevent catheter-associated infections is to avoid unnecessary catheterizations and to remove them when no longer necessary (117). Foley catheters should only be inserted when clinically indicated to decrease the risk of bacteriuria (5-10% / day  $\geq 2$  days after insertion) and infection. In patients with long-term indwelling catheters antibiotic coated catheters could be considered, without definitive evidence that they reduce infections. However, use of antibiotic-impregnated catheters in those expected to remain >5 days could be recommended only if a comprehensive strategy to reduce the rate of central line associated blood stream infections has been implemented without success. Replacement of central lines in the absence of infection is not recommended (118).

#### **Treatment of Infectious Complications**

##### **Recommendation**

1. ***We recommend that antibiotic therapy should be tailored to the specific pathogen once identified. If a pathogen is not identified, ongoing therapy and evaluation should be determined by the patient's clinical course (1B).***

**Rationale.** Discussing specific infection treatment algorithms is outside the scope of this manuscript (119); however, since severe sepsis is a common complication of cirrhotic patients with acute decompensation (120), important diagnostic and management strategies are highlighted in **Figure 4**. When working up a patient with suspected infection, inflammatory biomarkers such as serum C-reactive protein (CRP) or procalcitonin can be useful; one is not superior to the other (**Suppl. Table 3**) (121). Serum CRP levels increase to a lesser extent during infection in patients with more advanced liver disease, but can still be used to identify infection and improvement.

Once severe sepsis is suspected, a thorough evaluation should be promptly followed by antibiotic administration, since each hour delay impairs outcome (122). In patients with clinical improvement within 48-72 hours and a known pathogen, immediate tailoring of antibiotics is recommended; matrix-assisted laser desorption/ionization time of flight (MALDI-TOF) testing (123) in countries where it is commercially available (currently unavailable in the US) may facilitate de-escalation. In patients without clinical improvement empiric antifungal therapy and CT scan should be considered (124).

## Fungal Infections

### Recommendations

1. ***We do not recommend treatment in patients with asymptomatic candiduria (1D).***
2. ***We recommend antifungal therapy in intubated patients with yeast in sputum or bronchial lavages (BAL) with an additional positive fungal culture at another sterile site (1B).***
3. ***We recommend antifungal therapy in ICU patients without clinical improvement after 48 hours and in high prevalence (>5%) regions or with risk factors for development of invasive fungal infections (1D).***

**Rationale.** In addition to having an increased susceptibility to bacterial infections, patients with advanced liver disease are at higher risk for fungal infections likely due to significant immunologic impairment, increased intestinal permeability, frequent use of corticosteroids, malnutrition and performance of invasive procedures (125, 126).

In patients with multifocal candida colonization with clinical risk factors for infection but who remain in stable condition, preemptive therapy is not indicated. BAL candida isolation generally indicates

colonization but not infection (127). Initial therapy for candiduria should include Foley catheter removal or exchange. Although amphotericin bladder washes are generally not recommended, it may be useful for treatment of patients with refractory cystitis due to fluconazole-resistant candida species such as candida glabrata and krusei (128, 129). Antifungal therapy should be considered in patients with two positive cultures from different sites, isolated positive blood culture and in septic patients without improvement for 48 hours (**Fig. 4**)(129). As recommended in the general population, critically ill cirrhotic patients should receive echinocandins as first line therapy (129, 130). Azoles should be used during de-escalation after susceptibility has been confirmed.

Antifungal prophylaxis may be used in ICU patients without clinical improvement in high prevalence areas or in those with multiple risk factors for infection (corticosteroid use, prolonged microbial use, central venous catheter, total parenteral nutrition, high APACHE score, renal replacement therapy, or malnutrition)(131).

## ALTERATIONS IN HEMOSTASIS

Patients with acute decompensation of cirrhosis, especially those with ACLF, are in a fragile continuum between ineffective hemostasis and excessive coagulation. Alterations in primary hemostasis, secondary hemostasis and fibrinolysis results in disturbance of this balance which leads to either bleeding or thrombotic episodes (**Fig. 5**) (132-135). Pathophysiological conditions of ACLF that may further disturb cirrhotic hemostatic imbalance include hemodynamic instability (133, 136), endothelial dysfunction (133), development of endogenous heparin-like substances due to infection (133, 136) and renal dysfunction (137).

## Clinical and Laboratory Tests to Assess the Risk of Bleeding and Thrombosis

### **Recommendations**

1. ***INR does not provide an adequate assessment of hemostasis in cirrhosis (2B).***
2. ***We recommend against routine prophylactic use of fresh frozen plasma (FFP)(1B).***
3. ***We suggest maintaining platelet counts above  $50 \times 10^9/L$  in the presence of active bleeding (2C).***

4. ***We recommend a hemoglobin transfusion trigger of 7 mg/dl (1A). Erythropoietin supplementation does not have a role in the absence of chronic kidney disease (1B).***
5. ***Viscoelastic testing should be considered during liver transplantation and other major surgery (cardiac, major trauma). Its role in the ICU setting or prior to invasive procedures requires further evaluation (2C).***
6. ***We suggest anticoagulation with unfractionated/low molecular weight heparin in patients with occlusive portal vein thrombosis in the absence of bleeding risk factors (2C).***

### ***Rationale***

#### **Internationalized Ratio (INR) /Prothrombin Time (PT)**

The INR is based on the PT which itself depends on the level of procoagulant factors I, II, V, VII, and X. It does not account for deficiencies of the anti-coagulation system (especially low protein C), which may result in a hypercoagulable state not reflected in prolongation of the INR. Together with elevated endothelial-derived factor VIII, the low protein C causes thrombin generation to be normal or even high in cirrhosis (132). Inter-laboratory variation in the INR in cirrhosis (due to absence of normalization of thromboplastins to a standard based on liver disease) makes INR 'cut-off' values of little value (138). Furthermore, thrombin production does not improve when normal plasma is transfused despite improvements in INR (139). Standard doses of FFP rarely correct coagulopathy of cirrhosis (133, 140), and can be harmful due to increases in portal pressure during variceal bleeding (141).

#### **Platelet Count**

Despite thrombocytopenia in cirrhosis, platelet adhesion *in vitro* is preserved by increased levels of von Willebrand factor (decreased ADAMTS13) (133). Using thrombin (factor II) production as a surrogate for clot formation, platelet counts exceeding  $50 \times 10^9/L$  are associated with adequate thrombin formation, making this a practical clinical target in the setting of active bleeding or as prophylaxis prior to procedures (133, 142). However, prophylactic transfusion of a single adult platelet unit is of marginal benefit in increasing the platelet count to target levels (143). Despite laboratory data, there is no clinical evidence of a definitive threshold that correlates with increase bleeding risk during surgery (i.e. liver transplant) or invasive procedures (including liver biopsy).



### **Hemoglobin Targets**

A recent study demonstrated that a restrictive hemoglobin transfusion target (7 mg/dl) was not inferior to a liberal strategy (9 mg/dl), and may have benefit in patients with Child Pugh A and B (144). Endogenous erythropoietin levels are elevated in cirrhotic patients and correlate with the severity of portal hypertension (145). Exogenous erythropoietin stimulates increased thrombopoiesis and platelet reactivity possibly exacerbating the risk of thrombosis (146).

### **Viscoelastic Tests of Whole Blood Coagulation**

Viscoelastic tests, which include thromboelastography (TEG), thromboelastometry (ROTEM) and sonorheometry, offer a means of assessing the activity of pro- and anti-coagulant pathways as well as providing a means of recognizing hyperfibrinolysis or premature clot dissolution (147). The tests are *in vitro* assays and do not account for the *in vivo* contributions of the endothelium and blood flow. Assessment of clotting can be performed in 10-20 minutes; however, assessment of fibrinolysis takes 30-60 minutes (148). Viscoelastic testing suggests that hypercoagulability is more prevalent in patients with cholestatic liver disease, acute liver failure and nonalcoholic steatohepatitis (149, 150). The management of patients with hypercoagulability on viscoelastic testing is not clear; however, pro-coagulants and antifibrinolytics should be used cautiously in these patients.

### **Venous Thromboembolic Disease and Anticoagulant Therapy**

Increased risks of venous thromboembolic disease (0.5-2% absolute risks) have been demonstrated in cirrhotic patients, especially in those patients with hypoalbuminemia (151, 152). Rates of portal vein thrombosis have been reported as approximately 8% per year with morbidity and mortality at one year impacted by prophylactic anticoagulation (153, 154). Anticoagulation demonstrates the most utility in patients with more extensive portal vein and mesenteric thrombosis in the absence of other risk factors for bleeding (153, 155). Low molecular weight heparin does not appear to increase risk of variceal bleeding (156) and is likely the safest choice. However it should be considered that it has an increased clinical effect despite decreased antithrombin III levels in cirrhotic patients (157).

## Bleeding Risks for Minimally Invasive and Surgical Procedures

### *Recommendations*

1. *We suggest transfusion to a platelet count above  $50 \times 10^9/L$  prior to minimally invasive procedures (2C).*
2. *During surgical procedures, viscoelastic testing should be considered to guide coagulation management (2C).*
3. *We suggest maintaining fibrinogen levels  $> 1.5$  g/L in patients with significant bleeding or during invasive / surgical procedures (2C).*

**Rationale.** Bleeding rates after minimally invasive procedures in cirrhotic patients have been demonstrated to be low for paracentesis (0-3.3%) and thoracentesis (2%) (158). Bleeding does not appear to correlate with platelet count or INR. Reported incidence of major bleeding complications after liver biopsy was between 0.22 and 0.58% with a 0.1% mortality. Bleeding rates were higher in patients with advanced hepatic fibrosis and platelet count  $\leq 60 \times 10^9/L$  (159, 160). Transjugular liver biopsy has been shown to be relatively safe even in those patients with decreased platelet count or prolonged INR (161). Risk of bleeding after liver surgery has been shown to correlate with surgical and hemostatic techniques rather than coagulation parameters (162). Although the optimal fibrinogen level is uncertain (normal 2-4.5 g/L), in bleeding/surgical patients, fibrinogen levels of  $> 1$  g/L are recommended (163, 164). More recent guidelines suggest higher levels ( $>1.5$ -2.0 g/L) are beneficial in major trauma with significant bleeding, a recommendation which aligns with *in vitro* levels required for optimal clot formation time on viscoelastic testing (165, 166). The routine use of viscoelastic testing during liver transplantation appears well established as a means to determine global coagulation status (167).

## Role of Novel Coagulation Agents/Complexes

### *Recommendations*

1. *We suggest prothrombin complex concentrates before invasive procedures preferably guided by viscoelastic testing (2D).*
2. *We recommend against routine use of thrombopoietin receptor agonists (1B).*

- 3. We suggest antifibrinolytic therapy (tranexamic acid or  $\epsilon$ -aminocaproic acid) use in decompensated cirrhosis with bleeding when hyperfibrinolysis is suspected or proven. Although safe, its clinical efficacy has not been established (2C).**

### **Rationale**

#### **Prothrombin Complexes**

Prothrombin complex concentrates (PCC) are available as 3-factor (FII, IX, X) and 4-factor products (same factors plus FVII). Some contain endogenous anticoagulants (protein C, protein S, antithrombin III) with or without heparin in an attempt to lessen the thrombotic risk (168). Thrombotic complications in ACLF patients may be reduced by limiting repeat dosing of PCCs. Factor II and X have long half-lives (60 and 30 hrs. respectively) and may accumulate during repeated administration. Thromboelastometry-guided PCC administration, when compared to FFP transfusion for massive trauma, resulted in a higher likelihood of avoidance of red blood cell and platelet transfusion (169).

#### **Thrombopoietin Receptor Agonists**

In trials, the oral thrombopoietin receptor agonist eltrombopag increased platelet count in thrombocytopenic HCV patients, improving tolerance of anti-HCV therapy (170). However, in the ELEVATE study, 6 eltrombopag-treated patients developed portal vein thrombosis (171). Nplate (romiplostim), administered to thrombocytopenic HCV patients prior to procedures, improved platelet counts and facilitated interventions without experiencing procedural bleeding or thrombosis (172). However, other reports suggest increased thrombotic risk, particularly in patients with platelet counts over  $200 \times 10^9/L$  (173).

#### **Antifibrinolytics**

Aprotinin, the most extensively studied antifibrinolytic, is efficacious for reducing transfusion requirements during transplant (174, 175). Aprotinin has been controversial and was withdrawn from the market in the wake of a cardiac surgery trial showing increased mortality (176). In an uncontrolled study,  $\epsilon$ -aminocaproic acid (Amicar) was deemed effective and safe for treatment of hyperfibrinolysis in patients with cirrhosis (177). Viscoelastic testing during antifibrinolytic therapy is recommended.

## NEUROLOGIC DYSFUNCTION

Mechanisms behind neurological dysfunction, mostly which is caused by hepatic encephalopathy (HE) in hospitalized cirrhotic patients, are varied and are often overlapping with concurrent or precipitating illnesses such as infections and electrolyte abnormalities (178). Studies of the brain have demonstrated alterations in ammonia metabolism, brain and systemic inflammation, and changes in cerebral blood flow and oxygenation (179).

## Diagnosis of HE

### *Recommendations*

1. *We suggest brain imaging only be used for overt HE at its first occurrence if: a) the onset of the symptoms is abrupt and severe, b) there are focal neurological signs, or c) there is limited or no response to treatment of the precipitating factor and/or to ammonia lowering strategies. Electroencephalogram (EEG) can be used to exclude other causes of altered mental status (2D).*
2. *Measurement of fasting ammonia levels can be informative only if it is normal in a confused, disorientated or comatose patient with cirrhosis (2D).*

**Rationale.** The differential diagnosis of HE is vast and should be rigorously investigated (**Table 5**) (10, 23, 179, 180). EEG changes, are non-specific and of limited value in the diagnosis of HE, nevertheless they can assess HE severity and exclude other causes of altered mental status (181). The risk of intra-cerebral hemorrhage is increased in cirrhotic patients and thus, brain imaging could be useful to exclude other causes of altered mental status (182).

To differentiate HE from other conditions, fasting ammonia levels can be relevant since, in a confused, disorientated or comatose cirrhotic patient, the finding of normal plasma ammonia levels suggests an alternative cause of neuropsychiatric abnormalities (179). Nevertheless, one should be warned against the use of high ammonia levels alone for purpose of diagnosing of HE since false positive results are frequent.

## Grading HE

**Recommendations**

1. *We recommend the use of West-Haven criteria (WHC) for clinical use provided it is refined using tools such as clinical HE staging scale (CHESS), HE scoring algorithm (HESA) or modified orientation log (MO-log) (1C).*
2. *We recommend the Glasgow coma scale (GCS) for clinical use and to guide need for airway protection (1B).*
3. *We suggest head Imaging studies and EEG only to exclude other causes especially when there is lack of response to therapy (2D).*

**Rationale.** Grading of mental status is important to assess and document the progression of disease and the impact of treatment. Currently there are no available tools that reliably distinguish HE from other etiologies of metabolic encephalopathy. Although simplicity and familiarity favor usage of the WHC to grade and monitor HE for clinical purposes, these criteria are not reliable in the earlier stages and therefore other questionnaires have been studied to refine the assessment (**Suppl. Table 4**) (183-187). Use of HESA, MO-log or CHESS may be considered for clinical research or practice where the outcome of interest is the presence, absence or change in HE. The GCS is a simple and widely utilized tool for characterizing neurologic dysfunction after traumatic brain injury (188) that has been applied to metabolic encephalopathy (189). Its greatest utility is defining the threshold (<8) below which airway protection may be required. Serial brain imaging and EEG assessments beyond exclusion of other causes and investigation of lack of improvement have not been shown to be clinically useful.

**Therapy for HE****Recommendations**

1. *We recommend the use of lactulose as the initial therapy for HE with close monitoring of electrolytes and the development of ileus (1C).*
2. *We do not recommend the use of neomycin, LOLA, IV albumin or other laxatives for the treatment of HE (1D).*
3. *We suggest albumin dialysis in patients with encephalopathy that is refractory to medical therapy (2C).*

**4. We recommend HE-specific therapies such as lactulose and rifaximin to be started to prevent recurrent episodes (1A).**

**Rationale.** In patients with altered mental status, specific therapies for HE is often initiated along with treatment of the precipitating factors such as GI bleeding, electrolyte disorders, renal dysfunction, medications (**Fig. 6**). Recurrence of HE has emerged as one of the leading causes for re-admission in cirrhotic patients (190). Lactulose, rifaximin and the probiotic VSL#3 have been shown to prevent HE recurrence (191-193).

Lactulose: The use of lactulose in hospitalized cirrhotic patients is hampered by trials with low sample sizes (194). Nevertheless, it continues to be used as first-line therapy for HE. The specific mode of administration is critical to prevent aspiration, especially in advanced stages of HE and over-administration can result in HE recurrence (195). The oral dose is 20 ml per hour till at least one bowel movement and then reduced to 20-30 ml BID to TID titrated to 2-3 soft bowel movements per day (179). Following an episode of acute variceal bleeding, studies have shown that mental status significantly improved after lactulose compared to no treatment and there was equivalent improvement with lactulose compared to rifaximin (196, 197). Studies comparing simple laxatives (polyethylene glycol (PEG) orally, saline enemas) to acidifying enemas or laxatives such as lactulose, lactitol and lactose, have shown a significant benefit of the “acidifying” enemas on mental status (198). In contrast a recent study showed superiority of PEG compared to lactulose in mental status improvement (199). Given the small number of patients in both studies further large-scale studies are needed to find out the differences between laxatives and potential acidifying agents.

Rifaximin: Current standard of care does not include rifaximin in the treatment of an HE episode but does not call for discontinuation if patient was already taking it as an outpatient (200). Mas et al. demonstrated equivalent global recovery, (despite greater improvement in ammonia and EEG in rifaximin) with rifaximin when it was directly compared to lactitol in patients with an episode of HE (201). This was followed by a study in which combined rifaximin and lactulose showed superior efficacy over lactulose alone (202). These two studies used different comparators and need to be replicated before routine rifaximin use can be recommended.



Albumin and Albumin Dialysis: Although in one controlled trial, treatment with albumin improved HE in patients with diuretic-related HE (203), in a randomized control trial, the primary endpoint of HE resolution was not reached but there was a survival benefit (179). Several studies have found a significant improvement in HE using albumin dialysis compared to standard medical therapy (204-207). However, only a few small studies have shown overall survival benefit (208-210). While the role of these therapies is being debated, their use as a bridge to liver transplant by providing temporary support of organ failure (liver, kidney and brain) is a potentially important goal in this situation.

Neomycin: Neomycin was the first drug approved for HE treatment in the US and was the standard to which lactulose was compared. Several underpowered studies with lactulose and neomycin demonstrated similar outcomes regarding mental status (179). However due to several adverse effects (nephro/oto-toxicity), the use of neomycin has fallen out of favor.

L-ornithine L-aspartate (LOLA): IV LOLA has been shown to improve mental status in one high-quality German trial, which has been replicated at least once in other countries. However, this drug is not available in the United States (211).

## **Intubation and Sedation**

### ***Recommendations***

- 1. We recommend intubation in patients with GCS <8 (1D).**
- 2. We recommend sedation with short acting agents and avoidance of benzodiazepines (1D).**

**Rationale.** All patients with HE WHC grade 3 or 4 and GCS <8 should be considered for intubation for airway protection (180). Short acting drugs such as propofol or dexmedetomidine should be used, with caution paid to hemodynamic side effects (212). Dexmedetomidine is associated with preservation of cognitive function (213) and reduced duration of mechanical ventilation in ICU patients (214) and may be used for the management of alcohol withdrawal which may allow decreased benzodiazepine administration (215). Both dexmedetomidine and propofol are associated with similar hemodynamic side effects (216).

**Conclusion**

ACLF is a recently recognized syndrome associated with multi organ/system failure(s) (liver, kidney, brain, coagulation, circulation and/or respiration) and with an extremely poor survival. These patients often require ICU care. The optimum treatment of patients with ACLF is evolving and further programmatic clinical research are essential to determine the mechanisms of organ failure in ACLF and to help develop effective methods that can bridge patients with ACLF to liver transplantation.

**Acknowledgement**

The authors wish to acknowledge the University of Southern California Keck School of Medicine for organizing the Consensus Meeting.

## References

1. Gines P, Quintero E, Arroyo V, Teres J, Bruguera M, Rimola A, Caballeria J, et al. Compensated cirrhosis: natural history and prognostic factors. *Hepatology* 1987;7:122-128.
2. Jalan R, Fernandez J, Wiest R, Schnabl B, Moreau R, Angeli P, Stadlbauer V, et al. Bacterial infections in cirrhosis: a position statement based on the EASL Special Conference 2013. *J Hepatol* 2014;60:1310-1324.
3. Jalan R, Gines P, Olson JC, Mookerjee RP, Moreau R, Garcia-Tsao G, Arroyo V, et al. Acute-on chronic liver failure. *J Hepatol* 2012;57:1336-1348.
4. Olson JC, Wendon JA, Kramer DJ, Arroyo V, Jalan R, Garcia-Tsao G, Kamath PS. Intensive care of the patient with cirrhosis. *Hepatology* 2011;54:1864-1872.
5. Atkins D, Best D, Briss PA, Eccles M, Falck-Ytter Y, Flottorp S, Guyatt GH, et al. Grading quality of evidence and strength of recommendations. *BMJ* 2004;328:1490.
6. Piano S, Rosi S, Maresio G, Fasolato S, Cavallin M, Romano A, Morando F, et al. Evaluation of the Acute Kidney Injury Network criteria in hospitalized patients with cirrhosis and ascites. *J Hepatol* 2013;59:482-489.
7. Wong F, O'Leary JG, Reddy KR, Patton H, Kamath PS, Fallon MB, Garcia-Tsao G, et al. New consensus definition of acute kidney injury accurately predicts 30-day mortality in patients with cirrhosis and infection. *Gastroenterology* 2013;145:1280-1288.
8. Tsien CD, Rabie R, Wong F. Acute kidney injury in decompensated cirrhosis. *Gut* 2013;62:131-137.
9. Barreto R, Fagundes C, Guevara M, Sola E, Pereira G, Rodriguez E, Graupera I, et al. Type-1 hepatorenal syndrome associated with infections in cirrhosis: natural history, outcome of kidney function, and survival. *Hepatology* 2014;59:1505-1513.
10. Adebayo D, Morabito V, Davenport A, Jalan R. Renal dysfunction in cirrhosis is not just a vasomotor nephropathy. *Kidney Int* 2015;87:509-515.
11. Gines P, Schrier RW. Renal failure in cirrhosis. *N Engl J Med* 2009;361:1279-1290.

12. Stadlbauer V, Wright GA, Banaji M, Mukhopadhy A, Mookerjee RP, Moore K, Jalan R. Relationship between activation of the sympathetic nervous system and renal blood flow autoregulation in cirrhosis. *Gastroenterology* 2008;134:111-119.
13. Nadim MK, Genyk YS, Tokin C, Fieber J, Ananthapanyasut W, Ye W, Selby R. Impact of the etiology of acute kidney injury on outcomes following liver transplantation: acute tubular necrosis versus hepatorenal syndrome. *Liver Transpl* 2012;18:539-548.
14. Bahirwani R, Campbell MS, Siropaides T, Markmann J, Olthoff K, Shaked A, Bloom RD, et al. Transplantation: impact of pretransplant renal insufficiency. *Liver Transpl* 2008;14:665-671.
15. Campbell MS, Kotlyar DS, Brensinger CM, Lewis JD, Shetty K, Bloom RD, Markmann JF, et al. Renal function after orthotopic liver transplantation is predicted by duration of pretransplantation creatinine elevation. *Liver Transpl* 2005;11:1048-1055.
16. Gonwa TA, McBride MA, Anderson K, Mai ML, Wadei H, Ahsan N. Continued influence of preoperative renal function on outcome of orthotopic liver transplant (OLT) in the US: where will MELD lead us? *Am J Transplant* 2006;6:2651-2659.
17. Hilmi IA, Damian D, Al-Khafaji A, Planinsic R, Boucek C, Sakai T, Chang CC, et al. Acute kidney injury following orthotopic liver transplantation: incidence, risk factors, and effects on patient and graft outcomes. *Br J Anaesth* 2015.
18. Davenport A, Cholongitas E, Xirouchakis E, Burroughs AK. Pitfalls in assessing renal function in patients with cirrhosis--potential inequity for access to treatment of hepatorenal failure and liver transplantation. *Nephrol Dial Transplant* 2011;26:2735-2742.
19. Macedo E, Bouchard J, Soroko SH, Chertow GM, Himmelfarb J, Ikizler TA, Paganini EP, et al. Fluid accumulation, recognition and staging of acute kidney injury in critically-ill patients. *Crit Care* 2010;14:R82.
20. Liu KD, Thompson BT, Ancukiewicz M, Steingrub JS, Douglas IS, Matthay MA, Wright P, et al. Acute kidney injury in patients with acute lung injury: impact of fluid accumulation on classification of acute kidney injury and associated outcomes. *Crit Care Med* 2011;39:2665-2671.

21. Xirouchakis E, Marelli L, Cholongitas E, Manousou P, Calvaruso V, Pleguezuelo M, Guerrini GP, et al. Comparison of cystatin C and creatinine-based glomerular filtration rate formulas with <sup>51</sup>Cr-EDTA clearance in patients with cirrhosis. *Clin J Am Soc Nephrol* 2011;6:84-92.
22. Gerbes AL, Gulberg V, Bilzer M, Vogeser M. Evaluation of serum cystatin C concentration as a marker of renal function in patients with cirrhosis of the liver. *Gut* 2002;50:106-110.
23. Francoz C, Nadim MK, Baron A, Prie D, Antoine C, Belghiti J, Valla D, et al. Glomerular filtration rate equations for liver-kidney transplantation in patients with cirrhosis: validation of current recommendations. *Hepatology* 2014;59:1514-1521.
24. Francoz C, Glotz D, Moreau R, Durand F. The evaluation of renal function and disease in patients with cirrhosis. *J Hepatol* 2010;52:605-613.
25. Gonwa TA, Jennings L, Mai ML, Stark PC, Levey AS, Klintmalm GB. Estimation of glomerular filtration rates before and after orthotopic liver transplantation: evaluation of current equations. *Liver Transpl* 2004;10:301-309.
26. Mindikoglu AL, Dowling TC, Weir MR, Seliger SL, Christenson RH, Magder LS. Performance of chronic kidney disease epidemiology collaboration creatinine-cystatin C equation for estimating kidney function in cirrhosis. *Hepatology* 2014;59:1532-1542.
27. De Souza V, Hadj-Aissa A, Dolomanova O, Rabilloud M, Rognant N, Lemoine S, Radenne S, et al. Creatinine- versus cystatine C-based equations in assessing the renal function of candidates for liver transplantation with cirrhosis. *Hepatology* 2014;59:1522-1531.
28. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. *Ann Intern Med* 1999;130:461-470.
29. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF, 3rd, Feldman HI, Kusek JW, et al. A new equation to estimate glomerular filtration rate. *Ann Intern Med* 2009;150:604-612.
30. Nadim MK, Kellum JA, Davenport A, Wong F, Davis C, Pannu N, Tolwani A, et al. Hepatorenal syndrome: the 8th International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. *Crit Care* 2012;16:R23.

31. Wong F, Nadim MK, Kellum JA, Salerno F, Bellomo R, Gerbes A, Angeli P, et al. Working Party proposal for a revised classification system of renal dysfunction in patients with cirrhosis. *Gut* 2011;60:702-709.
32. Belcher JM, Garcia-Tsao G, Sanyal AJ, Bhogal H, Lim JK, Ansari N, Coca SG, et al. Association of AKI with mortality and complications in hospitalized patients with cirrhosis. *Hepatology* 2013;57:753-762.
33. de Carvalho JR, Villela-Nogueira CA, Luiz RR, Guzzo PL, da Silva Rosa JM, Rocha E, Moraes Coelho HS, et al. Acute kidney injury network criteria as a predictor of hospital mortality in cirrhotic patients with ascites. *J Clin Gastroenterol* 2012;46:e21-26.
34. Fagundes C, Barreto R, Guevara M, Garcia E, Sola E, Rodriguez E, Graupera I, et al. A modified acute kidney injury classification for diagnosis and risk stratification of impairment of kidney function in cirrhosis. *J Hepatol* 2013;59:474-481.
35. Wong F, O'Leary JG, Reddy KR, Kamath PS, Garcia-Tsao G, Maliakkal B, Subramanian R, et al. A cut-off serum creatinine value of 1.5mg/dl for AKI - To be or not to be. *J Hepatol* 2015;62:741-743.
36. Mehta RL, Kellum JA, Shah SV, Molitoris BA, Ronco C, Warnock DG, Levin A. Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. *Crit Care* 2007;11:R31.
37. KDIGO. Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group KDIGO Clinical Practice Guideline for Acute Kidney Injury. *Kidney Int* 2012;Suppl.:1-138.
38. Angeli P, Gines P, Wong F, Bernardi M, Boyer TD, Gerbes A, Moreau R, et al. Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites. *J Hepatol* 2015;62:968-974.
39. Kellum JA, Sileanu FE, Murugan R, Lucko N, Shaw AD, Clermont G. Classifying AKI by Urine Output versus Serum Creatinine Level. *J Am Soc Nephrol* 2015.
40. Macedo E, Malhotra R, Bouchard J, Wynn SK, Mehta RL. Oliguria is an early predictor of higher mortality in critically ill patients. *Kidney Int* 2011;80:760-767.
41. Macedo E, Malhotra R, Claire-Del Granado R, Fedullo P, Mehta RL. Defining urine output criterion for acute kidney injury in critically ill patients. *Nephrol Dial Transplant* 2011;26:509-515.



42. Siew ED, Matheny ME, Ikizler TA, Lewis JB, Miller RA, Waitman LR, Go AS, et al. Commonly used surrogates for baseline renal function affect the classification and prognosis of acute kidney injury. *Kidney Int* 2010;77:536-542.
43. Zavada J, Hoste E, Cartin-Ceba R, Calzavacca P, Gajic O, Clermont G, Bellomo R, et al. A comparison of three methods to estimate baseline creatinine for RIFLE classification. *Nephrol Dial Transplant* 2010;25:3911-3918.
44. Siew ED, Davenport A. The growth of acute kidney injury: a rising tide or just closer attention to detail? *Kidney Int* 2015;87:46-61.
45. Gluud LL, Christensen K, Christensen E, Krag A. Systematic review of randomized trials on vasoconstrictor drugs for hepatorenal syndrome. *Hepatology* 2010;51:576-584.
46. Belcher JM, Garcia-Tsao G, Sanyal AJ, Thiessen-Philbrook H, Peixoto AJ, Perazella MA, Ansari N, et al. Urinary biomarkers and progression of AKI in patients with cirrhosis. *Clin J Am Soc Nephrol* 2014;9:1857-1867.
47. Belcher JM, Sanyal AJ, Peixoto AJ, Perazella MA, Lim J, Thiessen-Philbrook H, Ansari N, et al. Kidney biomarkers and differential diagnosis of patients with cirrhosis and acute kidney injury. *Hepatology* 2014;60:622-632.
48. Verna EC, Brown RS, Farrand E, Pichardo EM, Forster CS, Sola-Del Valle DA, Adkins SH, et al. Urinary neutrophil gelatinase-associated lipocalin predicts mortality and identifies acute kidney injury in cirrhosis. *Dig Dis Sci* 2012;57:2362-2370.
49. Fagundes C, Pepin MN, Guevara M, Barreto R, Casals G, Sola E, Pereira G, et al. Urinary neutrophil gelatinase-associated lipocalin as biomarker in the differential diagnosis of impairment of kidney function in cirrhosis. *J Hepatol* 2012;57:267-273.
50. Barreto R, Elia C, Sola E, Moreira R, Ariza X, Rodriguez E, Graupera I, et al. Urinary neutrophil gelatinase-associated lipocalin predicts kidney outcome and death in patients with cirrhosis and bacterial infections. *J Hepatol* 2014;61:35-42.
51. Ariza X, Sola E, Elia C, Barreto R, Moreira R, Morales-Ruiz M, Graupera I, et al. Analysis of a urinary biomarker panel for clinical outcomes assessment in cirrhosis. *PLoS One* 2015;10:e0128145.

52. Krag A, Moller S, Henriksen JH, Holstein-Rathlou NH, Larsen FS, Bendtsen F. Terlipressin improves renal function in patients with cirrhosis and ascites without hepatorenal syndrome. *Hepatology* 2007;46:1863-1871.
53. Albanese J, Leone M, Delmas A, Martin C. Terlipressin or norepinephrine in hyperdynamic septic shock: a prospective, randomized study. *Crit Care Med* 2005;33:1897-1902.
54. Nassar Junior AP, Farias AQ, LA DA, Carrilho FJ, Malbouisson LM. Terlipressin versus norepinephrine in the treatment of hepatorenal syndrome: a systematic review and meta-analysis. *PLoS One* 2014;9:e107466.
55. Davenport A, Will EJ, Davison AM. Effect of renal replacement therapy on patients with combined acute renal and fulminant hepatic failure. *Kidney Int Suppl* 1993;41:S245-251.
56. Bellomo R, Cass A, Cole L, Finfer S, Gallagher M, Lo S, McArthur C, et al. Intensity of continuous renal-replacement therapy in critically ill patients. *N Engl J Med* 2009;361:1627-1638.
57. Jalan R, Pavesi M, Saliba F, Amoros A, Fernandez J, Holland-Fischer P, Sawhney R, et al. The CLIF Consortium Acute Decompensation score (CLIF-C ADs) for prognosis of hospitalised cirrhotic patients without acute-on-chronic liver failure. *J Hepatol* 2015;62:831-840.
58. Moreau R, Jalan R, Gines P, Pavesi M, Angeli P, Cordoba J, Durand F, et al. Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. *Gastroenterology* 2013;144:1426-1437, 1437.
59. LeDoux D, Astiz ME, Carpati CM, Rackow EC. Effects of perfusion pressure on tissue perfusion in septic shock. *Crit Care Med* 2000;28:2729-2732.
60. Cecconi M, De Backer D, Antonelli M, Beale R, Bakker J, Hofer C, Jaeschke R, et al. Consensus on circulatory shock and hemodynamic monitoring. Task force of the European Society of Intensive Care Medicine. *Intensive Care Med* 2014;40:1795-1815.
61. Rhodes A, Cusack RJ, Newman PJ, Grounds RM, Bennett ED. A randomised, controlled trial of the pulmonary artery catheter in critically ill patients. *Intensive Care Med* 2002;28:256-264.
62. National Heart L, Blood Institute Acute Respiratory Distress Syndrome Clinical Trials N, Wiedemann HP, Wheeler AP, Bernard GR, Thompson BT, Hayden D, et al. Comparison of two fluid-management strategies in acute lung injury. *N Engl J Med* 2006;354:2564-2575.

63. Brandstrup B, Tonnesen H, Beier-Holgersen R, Hjortso E, Ording H, Lindorff-Larsen K, Rasmussen MS, et al. Effects of intravenous fluid restriction on postoperative complications: comparison of two perioperative fluid regimens: a randomized assessor-blinded multicenter trial. *Ann Surg* 2003;238:641-648.
64. Rosenberg AL, Dechert RE, Park PK, Bartlett RH. Review of a large clinical series: association of cumulative fluid balance on outcome in acute lung injury: a retrospective review of the ARDSnet tidal volume study cohort. *J Intensive Care Med* 2009;24:35-46.
65. Humphrey H, Hall J, Sznajder I, Silverstein M, Wood L. Improved survival in ARDS patients associated with a reduction in pulmonary capillary wedge pressure. *Chest* 1990;97:1176-1180.
66. Aspesi M, Gamberoni C, Severgnini P, Colombo G, Chiumello D, Minoja G, Tulli G, et al. The abdominal compartment syndrome. Clinical relevance. *Minerva Anesthesiol* 2002;68:138-146.
67. Sakka SG, Reinhart K, Meier-Hellmann A. Comparison of pulmonary artery and arterial thermodilution cardiac output in critically ill patients. *Intensive Care Med* 1999;25:843-846.
68. Monnet X, Teboul JL. Assessment of volume responsiveness during mechanical ventilation: recent advances. *Crit Care* 2013;17:217.
69. Biancofiore G, Critchley LA, Lee A, Yang XX, Bindi LM, Esposito M, Bisa M, et al. Evaluation of a new software version of the FloTrac/Vigileo (version 3.02) and a comparison with previous data in cirrhotic patients undergoing liver transplant surgery. *Anesth Analg* 2011;113:515-522.
70. McGowan JH, Cleland JG. Reliability of reporting left ventricular systolic function by echocardiography: a systematic review of 3 methods. *Am Heart J* 2003;146:388-397.
71. Funk GC, Doberer D, Kneidinger N, Lindner G, Holzinger U, Schneeweiss B. Acid-base disturbances in critically ill patients with cirrhosis. *Liver Int* 2007;27:901-909.
72. Galbois A, Bige N, Pichereau C, Boelle PY, Baudel JL, Bourcier S, Maury E, et al. Exploration of skin perfusion in cirrhotic patients with septic shock. *J Hepatol* 2015;62:549-555.
73. Finfer S, Bellomo R, Boyce N, French J, Myburgh J, Norton R. A comparison of albumin and saline for fluid resuscitation in the intensive care unit. *N Engl J Med* 2004;350:2247-2256.
74. Myburgh JA, Mythen MG. Resuscitation fluids. *N Engl J Med* 2013;369:1243-1251.
75. Arroyo V, Garcia-Martinez R, Salvatella X. Human serum albumin, systemic inflammation, and cirrhosis. *J Hepatol* 2014;61:396-407.

76. Ortega R, Gines P, Uriz J, Cardenas A, Calahorra B, De Las Heras D, Guevara M, et al. Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, nonrandomized study. *Hepatology* 2002;36:941-948.
77. Sort P, Navasa M, Arroyo V, Aldeguer X, Planas R, Ruiz-del-Arbol L, Castells L, et al. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. *N Engl J Med* 1999;341:403-409.
78. Gines A, Fernandez-Esparrach G, Monescillo A, Vila C, Domenech E, Abecasis R, Angeli P, et al. Randomized trial comparing albumin, dextran 70, and polygeline in cirrhotic patients with ascites treated by paracentesis. *Gastroenterology* 1996;111:1002-1010.
79. Moreau R, Valla DC, Durand-Zaleski I, Bronowicki JP, Durand F, Chaput JC, Dadamessi I, et al. Comparison of outcome in patients with cirrhosis and ascites following treatment with albumin or a synthetic colloid: a randomised controlled pilot trial. *Liver Int* 2006;26:46-54.
80. Sola-Vera J, Minana J, Ricart E, Planella M, Gonzalez B, Torras X, Rodriguez J, et al. Randomized trial comparing albumin and saline in the prevention of paracentesis-induced circulatory dysfunction in cirrhotic patients with ascites. *Hepatology* 2003;37:1147-1153.
81. Guevara M, Terra C, Nazar A, Sola E, Fernandez J, Pavesi M, Arroyo V, et al. Albumin for bacterial infections other than spontaneous bacterial peritonitis in cirrhosis. A randomized, controlled study. *J Hepatol* 2012;57:759-765.
82. Thevenot T, Bureau C, Oberti F, Anty R, Louvet A, Plessier A, Rudler M, et al. Effect of albumin in cirrhotic patients with infection other than spontaneous bacterial peritonitis. A randomized trial. *J Hepatol* 2015;62:822-830.
83. Schortgen F, Lacherade JC, Bruneel F, Cattaneo I, Hemery F, Lemaire F, Brochard L. Effects of hydroxyethylstarch and gelatin on renal function in severe sepsis: a multicentre randomised study. *Lancet* 2001;357:911-916.
84. Perner A, Haase N, Guttormsen AB, Tenhunen J, Klemenzson G, Aneman A, Madsen KR, et al. Hydroxyethyl starch 130/0.42 versus Ringer's acetate in severe sepsis. *N Engl J Med* 2012;367:124-134.
85. De Backer D, Biston P, Devriendt J, Madl C, Chochrad D, Aldecoa C, Brasseur A, et al. Comparison of dopamine and norepinephrine in the treatment of shock. *N Engl J Med* 2010;362:779-789.

86. O'Brien A, Clapp L, Singer M. Terlipressin for norepinephrine-resistant septic shock. *Lancet* 2002;359:1209-1210.
87. Morelli A, Rocco M, Conti G, Orecchioni A, De Gaetano A, Cortese G, Coluzzi F, et al. Effects of terlipressin on systemic and regional haemodynamics in catecholamine-treated hyperkinetic septic shock. *Intensive Care Med* 2004;30:597-604.
88. Delmas A, Leone M, Rousseau S, Albanese J, Martin C. Clinical review: Vasopressin and terlipressin in septic shock patients. *Crit Care* 2005;9:212-222.
89. Leone M, Albanese J, Delmas A, Chaabane W, Garnier F, Martin C. Terlipressin in catecholamine-resistant septic shock patients. *Shock* 2004;22:314-319.
90. Fede G, Spadaro L, Tomaselli T, Privitera G, Germani G, Tsochatzis E, Thomas M, et al. Adrenocortical dysfunction in liver disease: a systematic review. *Hepatology* 2012;55:1282-1291.
91. Harry R, Auzinger G, Wendon J. The clinical importance of adrenal insufficiency in acute hepatic dysfunction. *Hepatology* 2002;36:395-402.
92. Marik PE, Gayowski T, Starzl TE, Hepatic Cortisol R, Adrenal Pathophysiology Study G. The hepatoadrenal syndrome: a common yet unrecognized clinical condition. *Crit Care Med* 2005;33:1254-1259.
93. Tsai MH, Peng YS, Chen YC, Liu NJ, Ho YP, Fang JT, Lien JM, et al. Adrenal insufficiency in patients with cirrhosis, severe sepsis and septic shock. *Hepatology* 2006;43:673-681.
94. Arabi YM, Aljumah A, Dabbagh O, Tamim HM, Rishu AH, Al-Abdulkareem A, Knawy BA, et al. Low-dose hydrocortisone in patients with cirrhosis and septic shock: a randomized controlled trial. *CMAJ* 2010;182:1971-1977.
95. Fernandez J, Escorsell A, Zabalza M, Felipe V, Navasa M, Mas A, Lacy AM, et al. Adrenal insufficiency in patients with cirrhosis and septic shock: Effect of treatment with hydrocortisone on survival. *Hepatology* 2006;44:1288-1295.
96. Harry R, Auzinger G, Wendon J. The effects of supraphysiological doses of corticosteroids in hypotensive liver failure. *Liver Int* 2003;23:71-77.

97. Annane D, Sebille V, Charpentier C, Bollaert PE, Francois B, Korach JM, Capellier G, et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. *JAMA* 2002;288:862-871.
98. Qin N, Yang F, Li A, Prifti E, Chen Y, Shao L, Guo J, et al. Alterations of the human gut microbiome in liver cirrhosis. *Nature* 2014;513:59-64.
99. Wigg AJ, Roberts-Thomson IC, Dymock RB, McCarthy PJ, Grose RH, Cummins AG. The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia, and tumour necrosis factor alpha in the pathogenesis of non-alcoholic steatohepatitis. *Gut* 2001;48:206-211.
100. Kakiyama G, Pandak WM, Gillevet PM, Hylemon PB, Heuman DM, Daita K, Takei H, et al. Modulation of the fecal bile acid profile by gut microbiota in cirrhosis. *J Hepatol* 2013;58:949-955.
101. Wasmuth HE, Kunz D, Yagmur E, Timmer-Stranghoner A, Vidacek D, Siewert E, Bach J, et al. Patients with acute on chronic liver failure display "sepsis-like" immune paralysis. *J Hepatol* 2005;42:195-201.
102. Rolas L, Makhezer N, Hadjoudj S, El-Benna J, Djerdjouri B, Elkrief L, Moreau R, et al. Inhibition of mammalian target of rapamycin aggravates the respiratory burst defect of neutrophils from decompensated patients with cirrhosis. *Hepatology* 2013;57:1163-1171.
103. O'Brien AJ, Fullerton JN, Massey KA, Auld G, Sewell G, James S, Newson J, et al. Immunosuppression in acutely decompensated cirrhosis is mediated by prostaglandin E2. *Nat Med* 2014;20:518-523.
104. Bajaj JS, O'Leary JG, Reddy KR, Wong F, Olson JC, Subramanian RM, Brown G, et al. Second infections independently increase mortality in hospitalized patients with cirrhosis: the North American consortium for the study of end-stage liver disease (NACSELD) experience. *Hepatology* 2012;56:2328-2335.
105. de Franchis R, Baveno VF. Revising consensus in portal hypertension: report of the Baveno V consensus workshop on methodology of diagnosis and therapy in portal hypertension. *J Hepatol* 2010;53:762-768.

106. Chavez-Tapia NC, Barrientos-Gutierrez T, Tellez-Avila F, Soares-Weiser K, Mendez-Sanchez N, Gluud C, Uribe M. Meta-analysis: antibiotic prophylaxis for cirrhotic patients with upper gastrointestinal bleeding - an updated Cochrane review. *Aliment Pharmacol Ther* 2011;34:509-518.
107. Pauwels A, Mostefa-Kara N, Debenes B, Degoutte E, Levy VG. Systemic antibiotic prophylaxis after gastrointestinal hemorrhage in cirrhotic patients with a high risk of infection. *Hepatology* 1996;24:802-806.
108. Soriano G, Guarner C, Tomas A, Villanueva C, Torras X, Gonzalez D, Sainz S, et al. Norfloxacin prevents bacterial infection in cirrhotics with gastrointestinal hemorrhage. *Gastroenterology* 1992;103:1267-1272.
109. Wu CK, Wang JH, Lee CH, Wu KL, Tai WC, Lu SN, Hu TH, et al. The outcome of prophylactic intravenous cefazolin and ceftriaxone in cirrhotic patients at different clinical stages of disease after endoscopic interventions for acute variceal hemorrhage. *PLoS One* 2013;8:e61666.
110. Loomba R, Wesley R, Bain A, Csako G, Pucino F. Role of fluoroquinolones in the primary prophylaxis of spontaneous bacterial peritonitis: meta-analysis. *Clin Gastroenterol Hepatol* 2009;7:487-493.
111. Novella M, Sola R, Soriano G, Andreu M, Gana J, Ortiz J, Coll S, et al. Continuous versus inpatient prophylaxis of the first episode of spontaneous bacterial peritonitis with norfloxacin. *Hepatology* 1997;25:532-536.
112. Fernandez J, Navasa M, Planas R, Montoliu S, Monfort D, Soriano G, Vila C, et al. Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis. *Gastroenterology* 2007;133:818-824.
113. Grange JD, Roulot D, Pelletier G, Pariente EA, Denis J, Ink O, Blanc P, et al. Norfloxacin primary prophylaxis of bacterial infections in cirrhotic patients with ascites: a double-blind randomized trial. *J Hepatol* 1998;29:430-436.
114. Terg R, Fassio E, Guevara M, Cartier M, Longo C, Lucero R, Landeira C, et al. Ciprofloxacin in primary prophylaxis of spontaneous bacterial peritonitis: a randomized, placebo-controlled study. *J Hepatol* 2008;48:774-779.

115. Pande C, Kumar A, Sarin SK. Addition of probiotics to norfloxacin does not improve efficacy in the prevention of spontaneous bacterial peritonitis: a double-blind placebo-controlled randomized-controlled trial. *Eur J Gastroenterol Hepatol* 2012;24:831-839.
116. Huang SS, Septimus E, Kleinman K, Moody J, Hickok J, Avery TR, Lankiewicz J, et al. Targeted versus universal decolonization to prevent ICU infection. *N Engl J Med* 2013;368:2255-2265.
117. Hooton TM, Bradley SF, Cardenas DD, Colgan R, Geerlings SE, Rice JC, Saint S, et al. Diagnosis, prevention, and treatment of catheter-associated urinary tract infection in adults: 2009 International Clinical Practice Guidelines from the Infectious Diseases Society of America. *Clin Infect Dis* 2010;50:625-663.
118. Mermel LA, Allon M, Bouza E, Craven DE, Flynn P, O'Grady NP, Raad, II, et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 Update by the Infectious Diseases Society of America. *Clin Infect Dis* 2009;49:1-45.
119. Fernandez J, Gustot T. Management of bacterial infections in cirrhosis. *J Hepatol* 2012;56 Suppl 1:S1-12.
120. Gustot T, Durand F, Lebre C, Vincent JL, Moreau R. Severe sepsis in cirrhosis. *Hepatology* 2009;50:2022-2033.
121. Bajaj JS, Heuman DM, Hylemon PB, Sanyal AJ, White MB, Monteith P, Noble NA, et al. Altered profile of human gut microbiome is associated with cirrhosis and its complications. *J Hepatol* 2014;60:940-947.
122. Arabi YM, Dara SI, Memish Z, Al Abdulkareem A, Tamim HM, Al-Shirawi N, Parrillo JE, et al. Antimicrobial therapeutic determinants of outcomes from septic shock among patients with cirrhosis. *Hepatology* 2012;56:2305-2315.
123. Patel R. MALDI-TOF MS for the Diagnosis of Infectious Diseases. *Clin Chem* 2015;61:100-111.
124. Lau A, Chen S, Sleiman S, Sorrell T. Current status and future perspectives on molecular and serological methods in diagnostic mycology. *Future Microbiol* 2009;4:1185-1222.
125. Panasiuk A, Wysocka J, Maciorkowska E, Panasiuk B, Prokopowicz D, Zak J, Radomski K. Phagocytic and oxidative burst activity of neutrophils in the end stage of liver cirrhosis. *World J Gastroenterol* 2005;11:7661-7665.



126. Cheruvattath R, Balan V. Infections in Patients With End-stage Liver Disease. *J Clin Gastroenterol* 2007;41:403-411.
127. Meersseman W, Lagrou K, Spriet I, Maertens J, Verbeken E, Peetermans WE, Van Wijngaerden E. Significance of the isolation of *Candida* species from airway samples in critically ill patients: a prospective, autopsy study. *Intensive Care Med* 2009;35:1526-1531.
128. Tuon FF, Amato VS, Penteadó Filho SR. Bladder irrigation with amphotericin B and fungal urinary tract infection--systematic review with meta-analysis. *Int J Infect Dis* 2009;13:701-706.
129. Pappas PG, Kauffman CA, Andes D, Benjamin DK, Jr., Calandra TF, Edwards JE, Jr., Filler SG, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. *Clin Infect Dis* 2009;48:503-535.
130. Cornely OA, Bassetti M, Calandra T, Garbino J, Kullberg BJ, Lortholary O, Meersseman W, et al. ESCMID\* guideline for the diagnosis and management of *Candida* diseases 2012: non-neutropenic adult patients. *Clin Microbiol Infect* 2012;18 Suppl 7:19-37.
131. Dimopoulos G, Karabinis A, Samonis G, Falagas ME. Candidemia in immunocompromised and immunocompetent critically ill patients: a prospective comparative study. *Eur J Clin Microbiol Infect Dis* 2007;26:377-384.
132. Tripodi A, Primignani M, Chantarangkul V, Dell'Era A, Clerici M, de Franchis R, Colombo M, et al. An imbalance of pro- vs anti-coagulation factors in plasma from patients with cirrhosis. *Gastroenterology* 2009;137:2105-2111.
133. Caldwell SH, Hoffman M, Lisman T, Macik BG, Northup PG, Reddy KR, Tripodi A, et al. Coagulation disorders and hemostasis in liver disease: pathophysiology and critical assessment of current management. *Hepatology* 2006;44:1039-1046.
134. Giannini EG, Savarino V. Thrombocytopenia in liver disease. *Curr Opin Hematol* 2008;15:473-480.
135. Colucci M, Binetti BM, Branca MG, Clerici C, Morelli A, Semeraro N, Gresele P. Deficiency of thrombin activatable fibrinolysis inhibitor in cirrhosis is associated with increased plasma fibrinolysis. *Hepatology* 2003;38:230-237.
136. Montalto P, Vlachogiannakos J, Cox DJ, Pastacaldi S, Patch D, Burroughs AK. Bacterial infection in cirrhosis impairs coagulation by a heparin effect: a prospective study. *J Hepatol* 2002;37:463-470.

137. Noris M, Remuzzi G. Uremic bleeding: closing the circle after 30 years of controversies? *Blood* 1999;94:2569-2574.
138. Lisman T, Van Leeuwen Y, Adelmeijer J, Pereboom ITA, Haagsma EB, Van Den Berg AP, Porte RJ. Interlaboratory variability in assessment of the model of end-stage liver disease score. In: *Liver International*; 2008. p. 1344-1351.
139. Tripodi A, Chantarangkul V, Primignani M, Clerici M, Dell'era A, Aghemo A, Mannucci PM. Thrombin generation in plasma from patients with cirrhosis supplemented with normal plasma: considerations on the efficacy of treatment with fresh-frozen plasma. *Intern Emerg Med* 2012;7:139-144.
140. Youssef W. Role of fresh frozen plasma infusion in correction of coagulopathy of chronic liver disease: a dual phase study. In: *Am J Gastroenterol*; 2003. p. 1391-1394.
141. Zimmon DS, Kessler RE. The portal pressure-blood volume relationship in cirrhosis. *Gut* 1974;15:99-101.
142. Tripodi A, Primignani M, Chantarangkul V, Clerici M, Dell'Era A, Fabris F, Salerno F, et al. Thrombin generation in patients with cirrhosis: the role of platelets. *Hepatology* 2006;44:440-445.
143. Tripodi A, Primignani M, Chantarangkul V, Lemma L, Jovani M, Rebulla P, Mannucci PM. Global hemostasis tests in patients with cirrhosis before and after prophylactic platelet transfusion. *Liver Int* 2013;33:362-367.
144. Villanueva C, Colomo A, Bosch A, Concepcion M, Hernandez-Gea V, Aracil C, Graupera I, et al. Transfusion strategies for acute upper gastrointestinal bleeding. *N Engl J Med* 2013;368:11-21.
145. Yang YY, Lin HC, Lee WC, Huang YT, Hou MC, Lee FY, Chang FY, et al. Plasma erythropoietin level in patients with cirrhosis and its relationship to the severity of cirrhosis and renal function. *J Gastroenterol Hepatol* 2003;18:1156-1161.
146. Homoncik M, Jilma-Stohlawetz P, Schmid M, Ferlitsch A, Peck-Radosavljevic M. Erythropoietin increases platelet reactivity and platelet counts in patients with alcoholic liver cirrhosis: a randomized, double-blind, placebo-controlled study. *Aliment Pharmacol Ther* 2004;20:437-443.
147. Rijken DC, Kock EL, Guimaraes AH, Talens S, Darwish Murad S, Janssen HL, Leebeek FW. Evidence for an enhanced fibrinolytic capacity in cirrhosis as measured with two different global fibrinolysis tests. *J Thromb Haemost* 2012;10:2116-2122.

148. Girdauskas E, Kempfert J, Kuntze T, Borger MA, Enders J, Fassl J, Falk V, et al. Thromboelastometrically guided transfusion protocol during aortic surgery with circulatory arrest: a prospective, randomized trial. *J Thorac Cardiovasc Surg* 2010;140:1117-1124.
149. Krzanicki D, Sugavanam A, Mallett S. Intraoperative hypercoagulability during liver transplantation as demonstrated by thromboelastography. *Liver Transpl* 2013;19:852-861.
150. Ben-Ari Z, Panagou M, Patch D, Bates S, Osman E, Pasi J, Burroughs A. Hypercoagulability in patients with primary biliary cirrhosis and primary sclerosing cholangitis evaluated by thromboelastography. *J Hepatol* 1997;26:554-559.
151. Gulley D, Teal E, Suvannasankha A, Chalasani N, Liangpunsakul S. Deep vein thrombosis and pulmonary embolism in cirrhosis patients. *Dig Dis Sci* 2008;53:3012-3017.
152. Wu H, Nguyen GC. Liver cirrhosis is associated with venous thromboembolism among hospitalized patients in a nationwide US study. *Clin Gastroenterol Hepatol* 2010;8:800-805.
153. Francoz C, Belghiti J, Vilgrain V, Sommacale D, Paradis V, Condat B, Denninger MH, et al. Splanchnic vein thrombosis in candidates for liver transplantation: usefulness of screening and anticoagulation. *Gut* 2005;54:691-697.
154. Villa E, Camma C, Marietta M, Luongo M, Critelli R, Colopi S, Tata C, et al. Enoxaparin prevents portal vein thrombosis and liver decompensation in patients with advanced cirrhosis. *Gastroenterology* 2012;143:1253-1260 e1251-1254.
155. Englesbe MJ, Schaubel DE, Cai S, Guidinger MK, Merion RM. Portal vein thrombosis and liver transplant survival benefit. *Liver Transpl* 2010;16:999-1005.
156. Weeder PD, Porte RJ, Lisman T. Hemostasis in liver disease: implications of new concepts for perioperative management. *Transfus Med Rev* 2014;28:107-113.
157. Senzolo M, Rodriguez-Castro KI, Rossetto V, Radu C, Gavasso S, Carraro P, Zerbinati P, et al. Increased anticoagulant response to low-molecular-weight heparin in plasma from patients with advanced cirrhosis. *J Thromb Haemost* 2012;10:1823-1829.
158. Castellote J, Xiol X, Cortes-Beut R, Tremosa G, Rodriguez E, Vazquez S. Complications of thoracentesis in cirrhotic patients with pleural effusion. *Rev Esp Enferm Dig* 2001;93:566-575.

159. West J, Card TR. Reduced Mortality Rates Following Elective Percutaneous Liver Biopsies. *Gastroenterology* 2010;139:1230-1237.
160. Seeff LB, Everson GT, Morgan TR, Curto TM, Lee WM, Ghany MG, Shiffman ML, et al. Complication Rate of Percutaneous Liver Biopsies Among Persons With Advanced Chronic Liver Disease in the HALT-C Trial. *Clinical Gastroenterology and Hepatology* 2010;8:877-883.
161. Kalambokis G, Manousou P, Vibhakorn S, Marelli L, Cholongitas E, Senzolo M, Patch D, et al. Transjugular liver biopsy--indications, adequacy, quality of specimens, and complications--a systematic review. *J Hepatol* 2007;47:284-294.
162. Wei AC, Tung-Ping Poon R, Fan ST, Wong J. Risk factors for perioperative morbidity and mortality after extended hepatectomy for hepatocellular carcinoma. *Br J Surg* 2003;90:33-41.
163. Nascimento B, Goodnough LT, Levy JH. Cryoprecipitate therapy. *Br J Anaesth* 2014;113:922-934.
164. Levy JH, Welsby I, Goodnough LT. Fibrinogen as a therapeutic target for bleeding: a review of critical levels and replacement therapy. *Transfusion* 2014;54:1389-1405; quiz 1388.
165. Spahn DR, Bouillon B, Cerny V, Coats TJ, Duranteau J, Fernandez-Mondejar E, Filipescu D, et al. Management of bleeding and coagulopathy following major trauma: an updated European guideline. *Crit Care* 2013;17:R76.
166. Brozek JL, Akl EA, Alonso-Coello P, Lang D, Jaeschke R, Williams JW, Phillips B, et al. Grading quality of evidence and strength of recommendations in clinical practice guidelines. Part 1 of 3. An overview of the GRADE approach and grading quality of evidence about interventions. *Allergy* 2009;64:669-677.
167. Arshad F, Ickx B, van Beem RT, Polak W, Grune F, Nevens F, Ilmakunnas M, et al. Prothrombin complex concentrate in the reduction of blood loss during orthotopic liver transplantation: PROTON-trial. *BMC Surg* 2013;13:22.
168. Hanke AA, Joch C, Gorlinger K. Long-term safety and efficacy of a pasteurized nanofiltrated prothrombin complex concentrate (Beriplex P/N): a pharmacovigilance study. *Br J Anaesth* 2013;110:764-772.

169. Schochl H, Nienaber U, Maegele M, Hochleitner G, Primavesi F, Steitz B, Arndt C, et al. Transfusion in trauma: thromboelastometry-guided coagulation factor concentrate-based therapy versus standard fresh frozen plasma-based therapy. *Crit Care* 2011;15:R83.
170. McHutchison JG, Dusheiko G, Shiffman ML, Rodriguez-Torres M, Sigal S, Bourliere M, Berg T, et al. Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C. *N Engl J Med* 2007;357:2227-2236.
171. Afdhal NH, Giannini EG, Tayyab G, Mohsin A, Lee JW, Andriulli A, Jeffers L, et al. Eltrombopag before procedures in patients with cirrhosis and thrombocytopenia. *N Engl J Med* 2012;367:716-724.
172. Moussa MM, Mowafy N. Preoperative use of romiplostim in thrombocytopenic patients with chronic hepatitis C and liver cirrhosis. *J Gastroenterol Hepatol* 2013;28:335-341.
173. Moulis G, Bagheri H, Sailer L, Jonville-Bera AP, Weber E, Guy C, Petitpain N, et al. Are adverse drug reaction patterns different between romiplostim and eltrombopag? 2009-2013 French Pharmacovigilance assessment. *Eur J Intern Med* 2014;25:777-780.
174. Hendriks HG, van der Meer J, Klompmaker IJ, Choudhury N, Hagenaars JA, Porte RJ, de Kam PJ, et al. Blood loss in orthotopic liver transplantation: a retrospective analysis of transfusion requirements and the effects of autotransfusion of cell saver blood in 164 consecutive patients. *Blood Coagul Fibrinolysis* 2000;11 Suppl 1:S87-93.
175. Findlay JY, Rettke SR, Ereth MH, Plevak DJ, Krom RA, Kufner RP. Aprotinin reduces red blood cell transfusion in orthotopic liver transplantation: a prospective, randomized, double-blind study. *Liver Transpl* 2001;7:802-807.
176. Fergusson DA, Hebert PC, Mazer CD, Fremes S, MacAdams C, Murkin JM, Teoh K, et al. A comparison of aprotinin and lysine analogues in high-risk cardiac surgery. *N Engl J Med* 2008;358:2319-2331.
177. Gunawan B, Runyon B. The efficacy and safety of epsilon-aminocaproic acid treatment in patients with cirrhosis and hyperfibrinolysis. *Aliment Pharmacol Ther* 2006;23:115-120.
178. Ferenci P, Lockwood A, Mullen K, Tarter R, Weissenborn K, Blei AT. Hepatic encephalopathy--definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998. *Hepatology* 2002;35:716-721.

179. Cordoba J, Ventura-Cots M, Simon-Talero M, Amoros A, Pavesi M, Vilstrup H, Angeli P, et al. Characteristics, risk factors, and mortality of cirrhotic patients hospitalized for hepatic encephalopathy with and without acute-on-chronic liver failure (ACLF). *J Hepatol* 2014;60:275-281.
180. Romero-Gomez M, Montagnese S, Jalan R. Hepatic encephalopathy in patients with acute decompensation of cirrhosis and acute-on-chronic liver failure. *J Hepatol* 2015;62:437-447.
181. Guerit JM, Amantini A, Fischer C, Kaplan PW, Mecarelli O, Schnitzler A, Ubiali E, et al. Neurophysiological investigations of hepatic encephalopathy: ISHEN practice guidelines. *Liver Int* 2009;29:789-796.
182. Gronbaek H, Johnsen SP, Jepsen P, Gislum M, Vilstrup H, Tage-Jensen U, Sorensen HT. Liver cirrhosis, other liver diseases, and risk of hospitalisation for intracerebral haemorrhage: a Danish population-based case-control study. *BMC Gastroenterol* 2008;8:16.
183. Ortiz M, Cordoba J, Doval E, Jacas C, Pujadas F, Esteban R, Guardia J. Development of a clinical hepatic encephalopathy staging scale. *Aliment Pharmacol Ther* 2007;26:859-867.
184. Hassanein T, Blei AT, Perry W, Hilsabeck R, Stange J, Larsen FS, Brown RS, Jr., et al. Performance of the hepatic encephalopathy scoring algorithm in a clinical trial of patients with cirrhosis and severe hepatic encephalopathy. *Am J Gastroenterol* 2009;104:1392-1400.
185. Salam M, Matherly S, Farooq IS, Stravitz RT, Sterling RK, Sanyal AJ, Gibson DP, et al. Modified-orientation log to assess hepatic encephalopathy. *Aliment Pharmacol Ther* 2012;35:913-920.
186. Inouye SK, Kosar CM, Tommet D, Schmitt EM, Puella MR, Saczynski JS, Marcantonio ER, et al. The CAM-S: development and validation of a new scoring system for delirium severity in 2 cohorts. *Ann Intern Med* 2014;160:526-533.
187. Bajaj JS, Cordoba J, Mullen KD, Amodio P, Shawcross DL, Butterworth RF, Morgan MY, et al. Review article: the design of clinical trials in hepatic encephalopathy--an International Society for Hepatic Encephalopathy and Nitrogen Metabolism (ISHEN) consensus statement. *Aliment Pharmacol Ther* 2011;33:739-747.
188. Jennett B, Teasdale G, Braakman R, Minderhoud J, Knill-Jones R. Predicting outcome in individual patients after severe head injury. *Lancet* 1976;1:1031-1034.

189. Vilstrup H, Gluud C, Hardt F, Kristensen M, Kohler O, Melgaard B, Dejgaard A, et al. Branched chain enriched amino acid versus glucose treatment of hepatic encephalopathy. A double-blind study of 65 patients with cirrhosis. *J Hepatol* 1990;10:291-296.
190. Volk ML, Tocco RS, Bazick J, Rakoski MO, Lok AS. Hospital readmissions among patients with decompensated cirrhosis. *Am J Gastroenterol* 2012;107:247-252.
191. Sharma BC, Sharma P, Agrawal A, Sarin SK. Secondary prophylaxis of hepatic encephalopathy: an open-label randomized controlled trial of lactulose versus placebo. *Gastroenterology* 2009;137:885-891.
192. Bass NM, Mullen KD, Sanyal A, Poordad F, Neff G, Leevy CB, Sigal S, et al. Rifaximin treatment in hepatic encephalopathy. *N Engl J Med* 2010;362:1071-1081.
193. Dhiman RK, Agrawal S, Gupta T, Duseja A, Chawla Y. Chronic Liver Failure-Sequential Organ Failure Assessment is better than the Asia-Pacific Association for the Study of Liver criteria for defining acute-on-chronic liver failure and predicting outcome. *World J Gastroenterol* 2014;20:14934-14941.
194. Shawcross D, Jalan R. Dispelling myths in the treatment of hepatic encephalopathy. *Lancet* 2005;365:431-433.
195. Bajaj JS, Sanyal AJ, Bell D, Gilles H, Heuman DM. Predictors of the recurrence of hepatic encephalopathy in lactulose-treated patients. *Aliment Pharmacol Ther* 2010;31:1012-1017.
196. Maharshi S, Sharma BC, Srivastava S, Jindal A. Randomised controlled trial of lactulose versus rifaximin for prophylaxis of hepatic encephalopathy in patients with acute variceal bleed. *Gut* 2015;64:1341-1342.
197. Sharma P, Agrawal A, Sharma BC, Sarin SK. Prophylaxis of hepatic encephalopathy in acute variceal bleed: a randomized controlled trial of lactulose versus no lactulose. *J Gastroenterol Hepatol* 2011;26:996-1003.
198. Uribe M, Campollo O, Vargas F, Ravelli GP, Mundo F, Zapata L, Gil S, et al. Acidifying enemas (lactitol and lactose) vs. nonacidifying enemas (tap water) to treat acute portal-systemic encephalopathy: a double-blind, randomized clinical trial. *Hepatology* 1987;7:639-643.
199. Rahimi RS, Singal AG, Cuthbert JA, Rockey DC. Lactulose vs polyethylene glycol 3350--electrolyte solution for treatment of overt hepatic encephalopathy: the HELP randomized clinical trial. *JAMA Intern Med* 2014;174:1727-1733.

200. Patidar KR, Bajaj JS. Antibiotics for the treatment of hepatic encephalopathy. *Metab Brain Dis* 2013;28:307-312.
201. Mas A, Rodes J, Sunyer L, Rodrigo L, Planas R, Vargas V, Castells L, et al. Comparison of rifaximin and lactitol in the treatment of acute hepatic encephalopathy: results of a randomized, double-blind, double-dummy, controlled clinical trial. *J Hepatol* 2003;38:51-58.
202. Sharma BC, Sharma P, Lunia MK, Srivastava S, Goyal R, Sarin SK. A randomized, double-blind, controlled trial comparing rifaximin plus lactulose with lactulose alone in treatment of overt hepatic encephalopathy. *Am J Gastroenterol* 2013;108:1458-1463.
203. Jalan R, Kapoor D. Reversal of diuretic-induced hepatic encephalopathy with infusion of albumin but not colloid. *Clin Sci (Lond)* 2004;106:467-474.
204. Sen S, Davies NA, Mookerjee RP, Cheshire LM, Hodges SJ, Williams R, Jalan R. Pathophysiological effects of albumin dialysis in acute-on-chronic liver failure: a randomized controlled study. *Liver Transpl* 2004;10:1109-1119.
205. Hassanein TI, Tofteng F, Brown RS, Jr., McGuire B, Lynch P, Mehta R, Larsen FS, et al. Randomized controlled study of extracorporeal albumin dialysis for hepatic encephalopathy in advanced cirrhosis. *Hepatology* 2007;46:1853-1862.
206. Banares R, Nevens F, Larsen FS, Jalan R, Albillos A, Dollinger M, Saliba F, et al. Extracorporeal albumin dialysis with the molecular adsorbent recirculating system in acute-on-chronic liver failure: the RELIEF trial. *Hepatology* 2013;57:1153-1162.
207. Pares A, Deulofeu R, Cisneros L, Escorsell A, Salmeron JM, Caballeria J, Mas A. Albumin dialysis improves hepatic encephalopathy and decreases circulating phenolic aromatic amino acids in patients with alcoholic hepatitis and severe liver failure. *Crit Care* 2009;13:R8.
208. Heemann U, Treichel U, Loock J, Philipp T, Gerken G, Malago M, Klammt S, et al. Albumin dialysis in cirrhosis with superimposed acute liver injury: a prospective, controlled study. *Hepatology* 2002;36:949-958.
209. Mitzner SR, Stange J, Klammt S, Risler T, Erley CM, Bader BD, Berger ED, et al. Improvement of hepatorenal syndrome with extracorporeal albumin dialysis MARS: results of a prospective, randomized, controlled clinical trial. *Liver Transpl* 2000;6:277-286.



210. Jalan R, Sen S, Steiner C, Kapoor D, Alisa A, Williams R. Extracorporeal liver support with molecular adsorbents recirculating system in patients with severe acute alcoholic hepatitis. *J Hepatol* 2003;38:24-31.
211. Stauch S, Kircheis G, Adler G, Beckh K, Ditschuneit H, Gortelmeyer R, Hendricks R, et al. Oral L-ornithine-L-aspartate therapy of chronic hepatic encephalopathy: results of a placebo-controlled double-blind study. *J Hepatol* 1998;28:856-864.
212. Shehabi Y, Bellomo R, Reade MC, Bailey M, Bass F, Howe B, McArthur C, et al. Early goal-directed sedation versus standard sedation in mechanically ventilated critically ill patients: a pilot study\*. *Crit Care Med* 2013;41:1983-1991.
213. Goodwin HE, Gill RS, Murakami PN, Thompson CB, Lewin JJ, 3rd, Mirski MA. Dexmedetomidine preserves attention/calculation when used for cooperative and short-term intensive care unit sedation. *J Crit Care* 2013;28:1113.
214. Pasin L, Greco T, Feltracco P, Vittorio A, Neto CN, Cabrini L, Landoni G, et al. Dexmedetomidine as a sedative agent in critically ill patients: a meta-analysis of randomized controlled trials. *PLoS One* 2013;8:e82913.
215. Muzyk AJ, Kerns S, Brudney S, Gagliardi JP. Dexmedetomidine for the treatment of alcohol withdrawal syndrome: rationale and current status of research. *CNS Drugs* 2013;27:913-920.
216. Erdman MJ, Doepker BA, Gerlach AT, Phillips GS, Eljovich L, Jones GM. A comparison of severe hemodynamic disturbances between dexmedetomidine and propofol for sedation in neurocritical care patients. *Crit Care Med* 2014;42:1696-1702.
217. Lisman T, Porte RJ. Rebalanced hemostasis in patients with liver disease: evidence and clinical consequences. *Blood* 2010;116:878-885.

**Table 1. Chronic Liver Failure (CLIF) Consortium Organ Failure Score** ([www.clifconsortium.com](http://www.clifconsortium.com))

Organ System	Score = 1	Score = 2	Score = 3
Liver, bilirubin (mg/dl)	< 6	6 - ≤ 12	> 12
Kidney, creatinine (mg/dl)	< 2	2 - < 3.5	≥ 3.5 or renal replacement therapy
Brain, grade (West-Haven)	0	1 - 2	3 - 4
Coagulation, INR	< 2	2 - < 2.5	≥ 2.5
Circulation, MAP (mmHg)	≥ 70	< 70	Vasopressors
Respiratory PaO <sub>2</sub> / FiO <sub>2</sub> or	> 300	≤ 300 and > 200	≤ 200
SpO <sub>2</sub> / FiO <sub>2</sub>	> 358	> 214 and ≤ 357	≤ 214

MAP: mean arterial pressure; FiO<sub>2</sub>: fraction of inspired oxygen; PaO<sub>2</sub>: partial pressure of arterial oxygen; SpO<sub>2</sub>: pulse oximetric saturation

Table 2. Definition and Staging of Acute Kidney Injury

AKI Definition	AKI Stage Serum Creatinine Criteria			AKI Stage Urine Output Criteria		
	1	2	3	1	2	3
<b>AKIN (2007)(36)</b> Increase Scr $\geq 0.3$ mg/dl (26.5 $\mu\text{mol/L}$ ) within 48 hours; or increase Scr $\geq 1.5$ x baseline within 48 hours; or UO $< 0.5$ ml/kg/h x 6 hrs  Baseline Scr is first Scr measured	Increase $\geq 0.3$ mg/dl ( $> 26.5$ $\mu\text{mol/L}$ ) within 48 hrs or $\geq 1.5$ -2 x baseline	Increase 2 -3 x baseline	Increase 3 x baseline or Scr $> 4$ mg/dl ( $> 354$ $\mu\text{mol/L}$ ) with an acute rise $> 0.5$ mg/dl (44 $\mu\text{mol/L}$ ) or on RRT	$< 0.5$ ml/kg/hr x 6-12 hrs	$< 0.5$ ml/kg/hr x 12 hrs	$< 0.3$ ml/kg/hr x 24 hr or anuria x 12 hrs
<b>KDIGO (2012)(37)</b> Increase Scr $\geq 0.3$ mg/dl (26.5 $\mu\text{mol/L}$ ) within 48 h; or increase Scr $\geq 1.5$ x baseline, which is known or presumed to have occurred within the prior 7 days; or UO $< 0.5$ ml/kg/h for 6 hr  Unknown baseline Scr estimation based on the MDRD formula, assuming a normal GFR of approximately 75 to 100 ml/min/1.73 $\text{m}^2$	Increase $\geq 0.3$ mg/dl ( $> 26.5$ $\mu\text{mol/L}$ ) within 48 hrs or $\geq 1.5$ -2 x baseline	Increase 2 -3 x baseline	Increase 3 x baseline or Scr $> 4$ mg/dl ( $> 354$ $\mu\text{mol/L}$ ) with an acute rise $> 0.5$ mg/dl (44 $\mu\text{mol/L}$ ) or on RRT	$< 0.5$ ml/kg/hr x 6-12 hrs	$< 0.5$ ml/kg/hr x 12 hrs	$< 0.3$ ml/kg/hr x 24 hr or anuria x 12 hrs
<b>ADQI (2010)(30)</b> <b>AKI in Cirrhosis</b>  HRS-1 is a specific form of AKI	Increase Scr $\geq 0.3$ mg/dl (26.5 $\mu\text{mol/L}$ ) within 48 hours; or increase Scr $\geq 1.5$ x baseline	Increase $\geq 0.3$ mg/dl ( $> 26.5$ $\mu\text{mol/L}$ ) within 48 hrs or $\geq 1.5$ -2 x baseline	Increase 2 -3 x baseline	Increase 3 x baseline or Scr $> 4$ mg/dl ( $> 354$ $\mu\text{mol/L}$ ) with an acute rise $> 0.5$ mg/dl (44 $\mu\text{mol/L}$ ) or on RRT	-	-
<b>ICA (2015)(38)</b> <b>AKI in Cirrhosis</b>  Scr within 3 months can be used as baseline. In patients with more than one Scr value, value closest to hospital admission should be used. In patients without previous Scr, Scr on admission should be used	Increase Scr $\geq 0.3$ mg/dl ( $\geq 26.5$ $\mu\text{mol/L}$ ) within 48 hours; or increase Scr $\geq 50\%$ from baseline which is known, or presumed, to have occurred within the prior 7 days	Increase $\geq 0.3$ mg/dl ( $> 26.5$ $\mu\text{mol/L}$ ) within 48 hrs or $\geq 1.5$ -2 x baseline	Increase 2 -3 x baseline	Increase 3 x baseline or Scr $> 4$ mg/dl ( $> 354$ $\mu\text{mol/L}$ ) with an acute rise $> 0.5$ mg/dl (44 $\mu\text{mol/L}$ ) or on RRT	-	-

AKI: acute kidney injury; Scr: serum creatinine; RRT: renal replacement therapy; AKIN: acute kidney injury network; KDIGO: kidney disease improving global outcomes; ADQI: acute dialysis quality initiative; ICA: international club of ascites

Table 3. Methods to Assess Volume Status in Patients with Cirrhosis and their Limitations

Methods	Possible Limitations
<b>Clinical</b>	
Weight changes	Biased by ascites and edema
Arterial pressure	Lower in average during cirrhosis
Pulse	Lower in patients receiving beta-blockers
Physical examination	Possible edema at baseline
Urine output	Lower in patients with renal vasoconstriction (HRS)
Chest radiogram	Abnormalities due to ascites/pleural effusion
Clinical History (recent diuretic use, diarrhea, etc.)	
<b>Laboratory Variables</b>	
Blood lactate	Decreased blood lactate clearance
Central/mixed venous oxygen saturation	Not validated in cirrhosis
Urinary biochemistry	Decreased sodium excretion in patients with activation of the renin-angiotensin-aldosterone system
<b>Static Hemodynamic Variables</b>	
Central venous pressure	Invasive. Poor correlation with fluid responsiveness
Pulmonary artery measurements	Invasive
Echocardiographic variables	Single measurement. Not useful for continuous monitoring
<b>Dynamic Hemodynamic Variables</b>	
Passive leg raising	Unreliable in setting of intrabdominal hypertension
Stroke volume/pulse pressure variations	Not validated in cirrhosis
Pulmonary artery occlusive pressure	Invasive
Vena cava diameter	Not accurate in setting of ascites. Not validated in cirrhosis

**Table 4: Considerations for Management and Relisting Patients for Liver Transplantation after Common Bacterial and Fungal infections**

Infection	Characteristics	Recommendations
<b>Urine</b>	Asymptomatic Bacteriuria	Not a contraindication; antibiotic therapy peri-transplant (1D)
	Asymptomatic Candiduria	Not a contraindication (1D)
	UTI with negative blood cultures	Not a contraindication; antibiotic treatment peri-transplant (1D)
<b>SBP</b>	Bacterial SBP*	5 days of treatment (1B) Reactivate if repeat tap shows a >25% decrease in PMN count $\geq 48$ hours after treatment initiation (2D) and other clinical parameters document improvement.
	Fungal SBP	Requires a full course of therapy and a PMN count $< 250$ cells/mm <sup>3</sup> off treatment. Always rule out secondary cause (2D)**
<b>Pneumonia</b>	Pneumonia	Reactivate floor patients after $\geq 7$ days of therapy when clinical improvement is documented (1D)
		Imaging lags behind clinical improvement; is needed only in patients without clinical improvement (2D)
		Patients on ventilator may benefit from a tracheal aspirate to guide treatment (2D)
		ICU patients: clinical improvement is required to achieve oxygen levels above local standards (2D)
		Pleural effusion requires a thoracentesis. Parapneumonic effusion requires no additional intervention (1D)
<b>Bacteremia</b>	Central Line	Empyema requires drainage; complete course of antibiotics, VATS is sometimes required (2D)
		Follow infectious disease guidelines (118) (Suppl. Fig. 3)
	Spontaneous	Antibiotics for 7-14 days (1C) Likely source: bacterial translocation or skin. Reactivation can be considered before completion of antibiotics if patient has documented rapid clinical improvement with negative repeat blood cultures for $\geq 48$ hours (2D)
	Fungemia	Completion of a course of treatment with repeat negative blood cultures off therapy is required in addition to exclusion of a secondary source (2D)
<b>C. Difficile</b>	Diarrhea and repeat <i>C. difficile</i> toxin and PCR are not good assessment tools	Therapy for at least 7 days is required, in addition to clinical improvement and normalization of WBC prior to reactivation. When uncertain, a flex sig can be performed to assess mucosal healing (2D)
		Consider fidaxomicin therapy as initial therapy to decrease relapse rate (1B) and VRE colonization (2D)
<b>Cholecystitis</b>	Operative candidates	Surgical intervention (1A)
	Non-operative candidates	IV antibiotics are first line therapy (1D). C-tube placement should be considered in those without a clinical response. Endoscopic gallbladder stenting or aspiration should only be considered when C-tube placement is absolutely contraindication and IV antibiotics are failing. Transplant reactivation should occur after an adequate clinical response (2D)

UTI, urinary tract infection; SBP, spontaneous bacterial peritonitis; PMN, polymorphonuclear; VATS, video-assisted thoracic surgery; ICU, intensive care unit; PCR, polymerase chain reaction; WBC, white blood cell count; VRE, vancomycin-resistant enterococci.

\*Spontaneous bacterial infection of pleural fluid (spontaneous bacterial empyema) should be treated as SBP unless loculated (Level D1).

\*\*Fungi rarely cause a SBP. A secondary peritonitis is very likely when at least two of the following parameters are present in ascites: glucose levels  $< 50$  mg/dl, protein concentration  $> 10$  g/l, LDH concentration  $>$  normal serum levels (Runyon's criteria). Patients with gastrointestinal perforation also present high levels of amylase and bilirubin in ascitic fluid. Prompt abdominal CT must be performed to exclude secondary peritonitis.

Table 5. Differential Diagnosis for Hepatic Encephalopathy

<b>Diabetic (hypoglycemia, ketoacidosis, hyperosmolar, lactic acidosis)</b>
<b>Alcohol (intoxication, withdrawal, Wernicke)</b>
<b>Drugs (benzodiazepines, neuroleptics, opioids)</b>
<b>Renal dysfunction</b>
<b>Electrolyte disorders (hyponatraemia and hypercalcemia)</b>
<b>Neurological infections</b>
<b>Non convulsive epilepsy</b>
<b>Psychiatric disorders</b>
<b>Intracranial bleeding and stroke</b>
<b>Severe medical stressful events (organ failure and inflammation)</b>

**Fig. 1. Diagnostic Algorithm to Evaluate Acute Kidney Injury in the Hospitalized Patient with Decompensated Cirrhosis.**

AKI: acute kidney injury; Scr: serum creatinine; UO: urine output; CKD: chronic kidney disease; RRT: renal replacement therapy; Na: sodium

\* Fluid overload may mask serum creatinine increases

\*\* CKD based on 6-variable MDRD equation eGFR <60 ml/min

**Fig. 2. Algorithm for Patients with Suspected Type-1 HRS**

HRS: hepatorenal syndrome; RRT: renal replacement therapy

\*A trial of octreotide & midodrine (maximum 3 days) can be attempted prior to initiation of norepinephrine

**Fig. 3: Assessment and Management of Abnormal Cardiovascular Function in Critically Ill Cirrhotic Patient in Shock**

MAP: mean arterial pressure; CVP central venous pressure; Cl: chloride; NaCl: sodium chloride; HRS: hepatorenal syndrome; SBP: spontaneous bacterial peritonitis; IAP: intra-abdominal pressure; SVV: stroke volume variation

**Fig. 4. Algorithm for Workup of Patients with Severe Sepsis.**

\*Risk factors for MDR: long-term SBP prophylaxis, recent use of beta-lactams (last 3 months), infection by MDR bacteria in the last 6 months

\*\*MALDI-TOF testing is not commercially available in the United States at this time, but once available will likely be incorporated into routine culture analysis.

WBC, white blood cell count; CRP, C-reactive protein; UA, urine analysis; CXR, chest x-ray; MDR, multi-drug resistant; CA, community acquired; HCA, health care associated; NI, nosocomial infection; MALDI-TOF, Matrix Assisted Laser Desorption Ionization Time-Of-Flight; ID, infectious disease

**Fig. 5. Hemostasis Balance in Patients with Liver Disease. Modified from Lisman and Porte, *Blood* 2010 (217).**

**Fig. 6. Algorithm for the Management of Hepatic Encephalopathy (HE).**

RRT: renal replacement therapy; ACLF: acute on chronic liver failure

Figure 1






Figure 2




Figure 3




Figure 4




Figure 5




Figure 6

